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(57) ABSTRACT 
The various embodiments of the present disclosure relate 
generally to nano gels for the cellular delivery of therapeutics 
and methods of using the same. More particularly, the various 
embodiments of the present invention are directed to systems 
and methods for the targeted treatment of neoplastic using 
nano gel-based technologies. In an embodiment of the present 
invention, a nanogel-based delivery system comprises: a 
nanogel comprising a crosslinked polymer particle; and an 
active agent contained substantially within the nanogel, 
wherein the active agent is non-covalently associated with the 
nano gel. 
19 Claims, 6 Drawing Sheets 
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NANOGELS FOR CELLULAR DELIVERY OF 
THERAPEUTICS 
2 
lytes. These charged moieties form polyplexes with the 
siRNA, forming aggregates that can be taken up into the cells, 
thereby delivering the siRNA to the cytosol. However, these 
carriers can have notable drawbacks with respect to toxicity CROSS-REFERENCE TO RELATED 
APPLICATIONS 
This application, filed under 35 U.S.C. §371, is a U.S. 
National Stage Application of International Patent Applica-
tion Ser. No. PCT/US2009/047555, filed 16 Jun. 2009, 
entitled Nanogels for Cellualr Delivery of Therapeutics, 
which claims, under 35 U.S.C. §119(e), the benefit of U.S. 
Provisional Application Ser. No. 61/061,715, filed 16 Jun. 
2008, the entire contents and substance of which are hereby 
incorporated by reference as if fully set forth below. 
5 and difficulties in specific cell targeting, thereby giving rise to 
a need for alternative delivery methods. A number of new 
approaches have been reported that overcome some of the 
shortcomings of lipid-based approaches. For example, 
Schiffelers et al. used an RGD (Arg--Gly-Asp peptide 
10 ligand)-PEG-PEI complex to target siRNA to tumor neovas-
culature. (Cancer siRNA therapy by tumor selective delivery 
with ligand-targeted sterically stabilized nanoparticle. 
Nucleic Acids Res. 32 (2004)). Song et al. presented the use 
of a protamine-antibody fusion protein using the Fab frag-
STATEMENT REGARDING FEDERALLY 
SPONSORED RESEARCH 
15 ment ofHIV-1 envelope antibody for siRNA delivery. (Anti-
body mediated in vivo delivery of small interfering RNAs via 
cell-surface receptors. Nat. Biotechnol. 23, 709-717 (2005)). 
Another targeting motif has been the use ofliposomes in the 
This invention was made with U.S. Government support 
under Grant No. 1 R21EB 006499-01 awarded by the 20 
National Institutes of Health. The U.S. Government has cer-
tain Rights in the invention. 
TECHNICAL FIELD OF THE INVENTION 
form of an immunoliposome complex reported by Pirollo et 
al. (Materializing the Potential of Small Interfering RNA via 
a Tumor-Targeting Nanodelivery System. Cancer Res. 67, 
2938-2943 (2007)). A number of other similar approaches 
have been taken and these siRNA carriers have enabled cer-
tain degrees of success. However, issues of toxicity, leaki-
The various embodiments of the present disclosure relate 
generally to nano gels for the cellular delivery of therapeutics 
and methods of using the same. More particularly, the various 
embodiments of the present invention are directed to systems 
and methods for the targeted treatment of neoplastic disease 
using nanogel-based technologies. 
25 ness, and payload capacity still persist, especially in the con-
text of in vivo gene silencing. 
Accordingly, there is a need for systems and methods for 
the efficient cellular delivery of therapeutics. It is to the pro-
vision of such systems and methods for the efficient cellular 
30 delivery of therapeutics using nanogel-based technologies 
that the various embodiments of the present invention are 
directed. 
BACKGROUND OF THE INVENTION 
Significant effort has been invested in the design of colloi- 35 
dal drug carriers in order to improve drug localization and 
bioavailability. Ideally, an actively targeted particulate drug 
carrier will increase the therapeutic efficacy of a drug by 
delivery to the diseased site, while reducing drug-associated 
side effects. Attainment of this goal would greatly advance 40 
treatment of diseases (e.g., cancer) where the toxic effects of 
therapeutics administered systemically may outweigh their 
benefit. To date, many types of delivery vehicles have been 
explored for in vitro and in vivo drug delivery applications, 
including inorganic nanoparticles, polyelectrolyte com- 45 
plexes, liposomes, block co-polymer micelles, and polymeric 
nanoparticles. 
A particularly compelling phenomenon from the stand-
point of cancer therapy is RNA interference (RNAi). RNAi is 
a relatively new approach to gene silencing, which has been 50 
demonstrated effective both in vitro and in vivo. This tech-
nique generally employs small 21-25 nucleotide long double 
stranded small interfering RNAs (or siRNAs) to inhibit gene 
expression through degradation of a targeted mRNA. 
Whereas the potential for therapeutic oncology applications 55 
exist where siRNA would be used to specifically shut down 
genes necessary for tumor growth, the lack of efficient meth-
ods for in vivo siRNA delivery prevent widespread therapeu-
BRIEF SUMMARY OF THE INVENTION 
Various embodiments of the present invention are directed 
to nanogels for the cellular delivery of therapeutics and meth-
ods of using the same. More particularly, the various embodi-
ments of the present invention are directed to systems and 
methods for the targeted treatment of neoplastic disease using 
nanogel-based technologies. 
An aspect of the present invention comprises a nanogel-
based delivery system comprising: a nanogel comprising a 
crosslinked polymer particle; and an active agent contained 
substantially within the nanogel, wherein the active agent is 
non-covalently associated with the nanogel. In one embodi-
ment of the present invention, the crosslinked polymer par-
ticle comprises poly(N-isopropylmethacrylamide) and N,N'-
methylenebis(acrylamide). In some embodiments of the 
present invention, the nanogel further comprises a 
crosslinked polymer shell comprising a functionalization 
agent, wherein the crosslinked polymer shell is disposed sub-
stantially around the crosslinked polymer particle. IN such 
embodiments, the crosslinked polymer shell can comprise 
poly(N-isopropylmethacrylamide), N,N'-methylenebis 
(acrylamide), and aminopropylmethacryamide. 
In an embodiment of the present invention, the active agent 
is a small interfering ribonucleic acid (siRNA). More specifi-
cally, the siRNA can comprise substantial sequence identity 
to a target gene relevant to neoplastic disease. 
In an embodiment of the present invention, the nano gel can 
further comprise a targeting moiety, wherein the targeting 
moiety is attached to the crosslinked polymer shell through 
the functionalization agent, and wherein the targeting moiety 
tic use. In addition to the confounding issues associated with 
systemic, intravenous delivery of siRNA, its polyanionic 60 
nature and high molecular weight (-13 kDa) prevent trans-
port across the cell membrane. Thus, effective siRNA carriers 
must enable efficient transport through the vasculature to the 
tumor, and then must additionally enable intracellular deliv-
ery of the cargo. 65 is displayed on at least a portion of the crosslinked polymer 
shell. In such an embodiment, the targeting moiety can com-
prise a peptide having the amino acid sequence YSAYPDS-
A common method currently used for siRNA delivery in 
vitro employs cationic lipid-based carriers or polyelectro-
US 8,361,510 B2 
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VPMMSC (SEQ ID NO 1 ). In one embodiment of the present 
invention, the active agent can comprise a siRNA having 
substantial sequence identity to a gene encoding epidermal 
growth factor receptor. 
An aspect of the present invention comprises a method of 
delivering an active agent into a cell, the method comprising: 
contacting a nanogel with a cell, the nanogel comprising a 
crosslinked polymer particle, and an active agent contained 
substantially within the nanogel, wherein the active agent is 
non-covalently associated with the nano gel; and delivering an 10 
active agent to the cell. In one embodiment of the present 
invention, the active agent comprises a siRNA. In an embodi-
ments of the present invention, the crosslinked polymer par-
ticle comprises poly(N-isopropylmethacrylamide) and N,N'-
methylenebis(acrylamide ). 15 
In some embodiments of the present invention, the nano gel 
further comprises a targeting moiety and crosslinked polymer 
shell comprising a functionalization agent, the crosslinked 
polymer shell disposed substantially around the crosslinked 
polymer particle, wherein the targeting moiety is attached to 20 
the crosslinked polymer shell through the functionalization 
agent, and wherein the targeting moiety is displayed on at 
least a portion of the crosslinked polymer shell. In one 
embodiment, the crosslinked polymer shell comprises poly 
(N-isopropy lmethacrylamide ), N,N'-methy lenebis( acry la- 25 
mide), and aminopropylmethacryamide. 
A method of delivering an active agent into a cell can 
further comprise reducing expression of a target gene, 
wherein the siRNA has substantial sequence identity to the 
target gene. In one embodiment of the present invention, the 30 
target gene encodes one or more of an anti-apoptotic mol-
ecule, a growth factor, a growth factor receptor, a mitotic 
spindle protein, a cell cycle protein, an angiogenic factor, an 
oncogene, an intracellular signal transducer, or a molecular 
chaperone. In an exemplary embodiment of the present inven- 35 
tion, the targeting moiety comprises a peptide having the 
amino acid sequence YSAYPDSVPMMSC (SEQ ID NO 1 ), 
and wherein the active agent is a siRNA having substantial 
sequence identity to the target gene, the target gene encoding 
epidermal growth factor receptor. 40 
Another aspect of the present invention comprises a 
method for treating neoplastic disease comprising: adminis-
tering to a subject having neoplastic disease an effective 
amount of a nanogel comprising a crosslinked polymer par-
ticle; a crosslinked polymer shell comprising a functionaliza- 45 
ti on agent, wherein the crosslinked polymer shell is disposed 
substantially around the crosslinked polymer particle; a tar-
geting moiety, wherein the targeting moiety is attached to the 
crosslinked polymer shell through the functionalization 
agent, and wherein the targeting moiety is displayed on at 50 
least a portion of the crosslinked polymer shell; and an active 
agent contained substantially within the nano gel, wherein the 
active agent is non-covalently associated with the nanogel. 
In one embodiment of the present invention, the 
crosslinked polymer particle comprises poly(N-isopropyl- 55 
methacrylamide)andN,N'-methylenebis(acrylamide).Inone 
embodiment of the present invention, the crosslinked poly-
mer shell comprises poly(N-isopropylmethacrylamide), 
N,N'-methylenebis(acrylamide), and aminopropyl-
methacryamide. In one embodiment of the present invention, 60 
the active agent is a siRNA. 
According to the various embodiments of the present 
invention, a method for treating neoplastic disease can further 
comprise reducing expression of a target gene, wherein the 
siRNA has substantial sequence identity to the target gene. In 65 
such embodiments of the present invention, the target gene 
encodes one or more of an anti-apoptotic molecule, a growth 
4 
factor, a growth factor receptor, a mitotic spindle protein, a 
cell cycle protein, an angiogenic factor, an oncogene, an 
intracellular signal transducer, or a molecular chaperone. 
More specifically, in an embodiment of the present invention, 
the targeting moiety comprises a peptide having the amino 
acid sequence YSAYPDSVPMMSC (SEQ ID NO 1 ), and 
wherein the target gene encodes epidermal growth factor 
receptor. 
In some embodiments of the present invention, a method 
for treating neoplastic disease can further comprise increas-
ing sensitivity of the subject to a chemotherapeutic agent. In 
such embodiments, the chemotherapeutic agent can comprise 
paclitaxel or docetaxel. 
Other aspects and features of embodiments of the present 
invention will become apparent to those of ordinary skill in 
the art, upon reviewing the following description of specific, 
exemplary embodiments of the present invention in conjunc-
tion with the accompanying figures. 
BRIEF DESCRIPTION OF DRAWINGS 
FIG. 1 schematically illustrates the non-covalent encapsu-
lation of siRNA in peptide-targeted core/shell nano gels. 
FIGS. 2A and B graphically depict the differential weight 
fraction plots for (A) pNIPMAnl core nano gels and (B) pNIP-
MAnl core/shell nanogels, as determined by AFFF-MALLS. 
FIG. 3 graphically illustrates the siRNA release profile 
from nanogels at 3 7° C. in PBS containing 10% fetal bovine 
seruni. The error bars represent±one standard deviation about 
the mean value (n=3). 
FIGS. 4A and B provide confocal microscopy images of 
(A) Hey cells and (B) BG-1 cells following exposure to 
siGLO-loaded/YSA-conjugated pNIPAMAm nanogels, 
YSA-nanogels alone, unlabeled nanogels, and siGLO alone. 
FIG. 5 provides confocal microscopy images of Hey cells 
(top) following exposure to siGLO-loaded/YSA-conjugated 
nanogels after 1 h ephrin incubation, and (bottom) following 
exposure to siGLO-loaded/YSA-conjugated nanogels alone. 
FIGS. 6A and B show flow cytometry data comparing (A) 
cell autofluorescence (first peak) vs. cells incubated with 
YSA-pNIPMAm nanogels (second peak) and (B) cell autof-
luorescence (first peak) vs. cells incubated with SCR-pNIP-
MAnl nanogels (second peak). 
FIG. 7 demonstrates cell viability as determined with a Tox 
8 assay for untreated Hey cells and Hey cells following a four 
h incubation with EGFR siRNA-loaded YSA-labeled nano-
gels, YSA-labeled pNIPMAnl nanogels, unlabeled pNIP-
MAnl, or YSA peptide alone. Error bars represent±one stan-
dard deviation about the average value (n=3). 
FIG. 8 demonstrates EGFR expression, as determined by 
immunoblot, in Hey cells following a four hour incubation 
with either unloaded YSA-nanogels, unloaded non-targeted 
nanogels, or siRNA loaded YSA-nanogels. Error bars repre-
sent ±one standard deviation about the average value (n=3, 
*p<0.01 relative to untreated sample). 
FIGS. 9A and B demonstrate expression of (A) EphA2 and 
(B) EGFR in Hey and SK-OV-3 ovarian cancer cell lines. 
FIGS. lOA and B illustrate down-regulation of EGFR by 
siRNA-loaded nanogels. 
FIGS. llA and B illustrate down-regulation of EGFR by 
different concentrations of siRNA-loaded nanogels. 
FIG. 12 shows the Level ofEGFR in SK-OV-3 cells after 
treatment with siRNA-loaded nanogels. 
FIGS. 13A and B demonstrate chemosensitization of Hey 
cells to docetaxel after exposure to YSA-targeted, siRNA 
loaded nanogels. 
US 8,361,510 B2 
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FIGS. 14A and B show the effects of increasing concen-
trations of docetaxel on SK-OV-3 cells treated with siRNA-
loaded nanogels. 
DETAILED DESCRIPTION OF THE INVENTION 
An aspect of the present invention comprises a nanogel-
based delivery system comprising: a nanogel comprising a 
crosslinked polymer particle; and an active agent contained 
substantially within the nanogel, wherein the active agent is 
non-covalently associated with the nanogel. 
6 
embodiments, the nano gel 10 comprises a core 20 comprising 
the crosslinked polymer particle. As such, the terms 
"crosslinked polymer particle" and "core" may be used inter-
changeably throughout this disclosure. The nanogel can fur-
ther comprise a crosslinked polymer shell 30, wherein the 
shell is disposed substantially around the crosslinked poly-
mer particle. 
The shell can have an average thickness of about 5 nanom-
eters to about 300 nanometers in a solvent swollen state. In an 
10 exemplary embodiment of the present invention, a shell can 
have a thickness of about 10 nanometers to about 20 nanom-
As used herein, the term "nanogel" refers to a crosslinked 
polymer particle capable of absorbing a fluid and retaining at 
least a portion of the fluid to form a swollen crosslinked 
polymer particle. A nanogel can have many sizes, and these 15 
sizes are indicative of the nano gel in solvent swollen form. A 
nanogel can have an average longest cross-sectional dimen-
sion of about 10 nanometers (nm) to about 5 micrometers 
(µm). In some embodiments of the present invention, a nano-
gel can have an average longest cross-sectional dimension 20 
about 20 nm to about 1 µm. In one embodiment of the present 
invention, a nanogel may have an average longest cross-
sectional dimension of about 20 nm to about 200 nm. In an 
eters. In some embodiments of the present invention, the shell 
may comprise the same polymeric material as the crosslinked 
polymer particle; however, in some embodiments of the 
present invention, the shell may comprise a different poly-
meric material than that of the crosslinked polymer particle. 
Further, the shell and crosslinked polymer particle may have 
similar or different crosslink densities and hydrophobicities. 
The shell can comprise many suitable hydrophilic, hydro-
phobic, and amphiphilic polymers known in the art. In some 
embodiments of the present invention, the shell can comprise 
a hydrophilic polymer, including, but not limited to, acry-
lates, acrylamides, acetates, acrylic acids, vinyl alcohols, gly-
cols, polysaccharides, co-polymers thereof, or combinations exemplary embodiment of the present invention, a nanogel 
may have an average longest cross-sectional dimension of 25 
about 50 nm to about 100 nm. 
thereof. The crosslinker of the shell can be many suitable 
crosslinkers known in the art including, but not limited to, 
A crosslinked polymer particle can comprise a polymer 
and a crosslinker. A crosslinked polymer particle can com-
prise many suitable hydrophilic, hydrophobic, and 
amphiphilic polymers known in the art. In some embodiment 
of the present invention, a crosslinked polymer particle can 
comprise a hydrophilic polymer, including, but not limited to, 
acrylates, acrylamides, acetates, acrylic acids, vinyl alcohols, 
glycols, polysaccharides, co-polymers thereof, or combina-
tions thereof. In various embodiments of the present inven-
tion, the polymer can have many topologies including, but not 
limited to, a branched topology, a graft topology, a comb 
topology, a star topology, a cyclic topology, a network topol-
ogy, or combinations thereof, among others. The crosslinker 
of the polymer particles can be many suitable crosslinkers 
known in the art including, but not limited to, N,N',methyl-
enebis(acrylamide), poly( ethylene glycol) (PEG) diacrylate, 
N,N'-dihydroxyethylene-bisacrylamide, N,0-(dimethacry-
loyl)hydroxylamine, ethylene glycol dimethacrylate, divinyl-
benzene, or combinations thereof. 
In an exemplary embodiment of the present invention, a 
crosslinked polymer particle comprises poly(N-isopropyl-
methacrylamide) (pNIPMAm) and N,N'-methylenebis(acry-
lamide) (BIS). In such embodiments, pNIPMAm can com-
prise about 90% to about 99.9% of the crosslinked polymer 
particle. Accordingly, BIS can comprise about 10% to about 
0.1 % of the crosslinked polymer particle. 
Nanogels of the present invention are configured to sub-
stantially contain an active agent. One of ordinary skill in the 
N,N', methylenebis(acrylamide), poly(ethylene glycol) 
(PEG) diacry late, N,N'-dihydroxyethy lene-bisacry !amide, 
N,0-(dimethacryloyl)hydroxylamine, ethylene glycol 
30 dimethacrylate, divinylbenzene, or combinations thereof. 
The shell may further comprise a functionalization agent. 
A functionalization agent permits surface modification of the 
nanogel. A functionalization agent can comprise a chemoli-
gation motif. In an embodiment of the present invention, the 
35 chemoligation motif can be present at a concentration of 
about 0.5% to about 15%. A chemoligation motif can include, 
but is not limited to, an amine, a carboxyl group, an aldehyde, 
a hydrazide, a sulfhydryl, a hydroxyl, or a ketone. These 
chemoligation motifs can be used to perform 'click' chemis-
40 try (e.g., a Cu(I) catalyzed 3+2 dipolar cycloaddition) a Schiff 
base transformation, and combinations thereof, which permit 
surface modification of the nano gel. In embodiments of the 
present invention, the functionalization agent can comprise 
N-(2-hydroxypropyl) methacrylamide (HPMA), aminopro-
45 pylmethacryamide (APMA), aminoethylacrylate, among 
others. In an exemplary embodiment of the present invention, 
the functionalization agent is aminopropylmethacryamide. 
In an exemplary embodiment of the present invention, a 
shell comprises poly(N-isopropylmethacrylamide) (pNIP-
50 MAm), N,N'-methylenebis(acrylamide) (BIS), and amino-
propylmethacryamide (APMA). In such embodiments, 
pNIPMAm can comprise about 75% to about 99.9% of the 
shell, BIS can comprise about 10% to about 0.1 % of the shell, 
and APMA can comprise about 0.5% to about 15% of the 
55 shell. In an exemplary embodiment of the present invention, 
the shell comprises 97.5% NIPMAm, 2% BIS, and 0.5% 
APMA. 
art would realize that the composition and crosslink density of 
the crosslinked polymer particle can be varied based upon the 
characteristics of the active agent (e.g., size, charge, etc.). 
One of ordinary skill in the art would realize that the crosslink 
density (also referred to a mesh size) of the polymer particle 
may be varied by increasing the crosslinker concentration, 60 
decreasing the crosslinker length, or increasing the number of 
reactive sites on the crosslinker. Similarly, one of ordinary 
skill in the art would realize that the hydrophobicity of the 
polymer particle can be varied to accommodate active agents 
having various solubilities. 
A nanogel-based delivery system comprises an active 
agent contained substantially within the nanogel, wherein the 
active agent is non-covalently associated with the nano gel. As 
used herein, the term "active agent" can refer to one or more 
active agents or components, such as pharmacological com-
ponent, a therapeutic component, a diagnostic component, a 
drug component, a biological component or the like. Thus, 
65 the terms "active agent," "drug," "therapeutic," "diagnostic," 
"pharmaceutical," and the like may be used interchangeably 
throughout this disclosure. An active agent may also com-
In some embodiments of the present invention, the nano gel 
comprises a core-shell topology, as shown in FIG. 1. In such 
US 8,361,510 B2 
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prise one or more pharmaceutical additives including, but not 
limited to, solubilizers, emulsifiers, buffers, preservatives, 
carriers, suspending agents, thickening agents, stabilizers, 
inert components, and the like. 
As used herein, the term "active agent" can include, with-
out limitation, a biological or chemical compound such as a 
simple or complex organic or inorganic molecule, peptide, 
peptide mimetic, protein (e.g. antibody, growth factor), an 
antigen or immunogen, small interfering RNA (siRNA), or a 
polynucleotide, a virus, or a therapeutic agent. Organic or 
inorganic molecules can include, but are not limited to, a 
homogenous or heterogeneous mixture of compounds, 
including pharmaceuticals, radioisotopes, crude or purified 
plant extracts, and/or an entity that alters, inhibits, activates, 
or otherwise affects biological or biochemical events, includ-
ing classes of molecules (e.g., proteins, amino acids, pep-
tides, polynucleotides, nucleotides, carbohydrates, sugars, 
lipids, nucleoproteins, glycoproteins, lipoproteins, steroids, 
growth factors, chemoattractants, cytokines, chemokines, 
etc.) that are commonly found in cells and tissues, whether the 
molecules themselves are naturally-occurring or artificially 
created (e.g., by synthetic or recombinant methods). 
8 
strand (e.g., a hairpin). Interfering RNA typically has sub-
stantial or complete identity to the target gene. The sequence 
of the siRNA can correspond to the full length target gene, or 
a sub-sequence (i.e., a portion) thereof. siRNA includes inter-
fering RNA of about 15 to about 60 nucleotides, about 15 to 
about 50 nucleotides, or about 15 to about 40 nucleotides in 
length, more typically about 15 to about 30 nucleotides, 15 to 
about 25 nucleotides, or 19 to about 25 nucleotides, and is 
preferably about 21 to about 25 nucleotides, about 20 to about 
10 24 nucleotides, about 21 to about 22 nucleotides, or about 21 
to about 23 nucleotides. siRNA duplexes may comprise 3' 
overhangs of about 1 to about 4 nucleotides, preferably of 
about 2 to about 3 nucleotides, and 5' phosphate termini. The 
siRNA can be chemically synthesized or may be encoded by 
15 a plasmid (e.g., transcribed as sequences that automatically 
fold into duplexes with hairpin loops). siRNA can also be 
generated by cleavage oflonger dsRNA (e.g., dsRNA greater 
than about 25 nucleotides in length) with theE. coli RNase III 
or Dicer. These enzymes process the dsRNA into biologically 
20 active siRNA. Preferably, dsRNA are at least 50 nucleotides 
to about 100, 200, 300, 400, or 500 nucleotides in length. A 
dsRNA may be as long as 1000, 1500, 2000, 5000 nucleotides 
in length, or longer. The dsRNA can encode for an entire gene Examples of such agents include, but are not limited to, 
agents for gene therapy; analgesics; anti-arthritics; anti-asth-
matic agents; anti-cancer agents; anti-cholinergics; anti-con- 25 
vulsants; anti-depressants; anti-diabetic agents; anesthetics; 
antibiotics; antigens; anti-histamines; anti-infectives; anti-
inflammatory agents; anti-microbial agents; anti-fungal 
agents, anti-Parkinson agents; anti-spasmodics; anti-prurit-
ics; anti-psychotics; anti-pyretics; anti-viral agents; nucleic 
acids; DNA; RNA; siRNA; polynucleotides; nucleosides; 
nucleotides; amino acids; peptides; proteins; carbohydrates; 
lectins; lipids; fats; fatty acids; viruses; immunogens; anti-
bodies and fragments thereof; sera; immunostimulants; 
immunosuprressants; cardiovascular agents; channel block-
transcript or a partial gene transcript. 
The siRNA of the present invention can comprise RNA 
having substantial or complete identity to the target genes 
involved many diseases. In an exemplary embodiment of the 
present invention, the siRNA can comprise RNA having sub-
stantial or complete identity to a target gene relevant to neo-
30 plastic disease (i.e., cancer), including but not limited to, an 
anti-apoptotic molecule, a growth factor, a growth factor 
receptor, a mitotic spindle protein, a cell cycle protein, an 
angiogenic factor, an oncogene, an intracellular signal trans-
ducer, a molecular chaperone, and combinations thereof. The 
35 term "neoplastic disease" is intended to refer to hyperplasia, 
tumors, tumorigenesis, cancer, metastasis, cells that have 
uncontrolled growth, and the like. A person of ordinary skill 
in the art would realize that gene expression analysis and 
proteomic analysis of neoplastic cells may prove useful in the 
ers (e.g., potassium channel blockers, calcium channel block-
ers, beta-blockers, alpha-blockers); anti-arrhythmics; anti-
hypertensives; inhibitors of DNA, RNA, or protein synthesis; 
neurotoxins; vasodilating agents; vasoconstricting agents; 
gases, growth factors; growth inhibitors; hormones; steroids; 
steroidal and non-steroidal anti-inflammatory agents; corti-
costeroids; angiogenic agents; anti-angiogenic agents; hyp-
notics; muscle relaxants; muscle contractants; sedatives; 
tranquilizers; ionized and non-ionized active agents; metals; 
small molecules; pharmaceuticals; hemotherapeutic agents; 
wound healing agents; indicators of change in the bio-envi-
ronment; enzymes; enzyme inhibitors; nutrients; vitamins; 
minerals; coagulation factors; anticoagulants; anti-throm-
botic agents; neurochemicals (e.g., neurotransmitters); cellu-
40 identification of suitable target genes. 
As used herein, the term "substantial identity" of poly-
nucleotide sequences means that a polynucleotide includes a 
sequence that has at least 51 %, 52%, 53%, 54%, 55%, 56%, 
57%, 58%, 59%, 60%, 61 %, 62%, 63%, 64%, 65%, 66%, 
45 67%, 68%, or 69%, 70%, 71 %, 72%, 73%, 74%, 75%, 76%, 
77%, 78%, or 79%, preferably at least 80%, 81 %, 82%, 83%, 
84%, 85%, 86%, 87%, 88%, or 89%, more preferably at least 
90%, 91 %, 92%, 93%, or 94%, and most preferably at least 
95%, 96%, 97%, 98%, or 99% sequence identity, compared to 
lar receptors; radioactive materials; contrast agents (e.g., 
fluorescence, magnetic, radioactive); nanoparticles (e.g., 
magnetic, semiconductor, dielectric, or metal); vaccines; 
modulators of cell growth; modulators of cell adhesion; cell 
response modifiers; cells; chemical or biological materials or 
compounds that induce a desired biological or pharmacologi-
50 a reference sequence. 
In an exemplary embodiment of the present invention, the 
target gene comprises the epidermal growth factor receptor 
(EGFR). In such embodiments, the siRNA has substantial or 
complete identity to at least a portion of the EGFR gene. 
cal effect; and combinations thereof. 
55 Using the nanogel systems of the present invention, EGFR 
expression can be reduced for at least 48 hours, for at least 
about 72 hours, for at least about 96 hours, or for at least about 
120 hours. 
In an exemplary embodiment of the present invention, the 
active agent is a small interfering RNA (siRNA). As used 
herein, the terms "small interfering RNA," "siRNA," "inter-
fering RNA" or "RNAi" or "interfering RNA sequence" 60 
refers to double-stranded RNA (i.e., duplex RNA) that targets 
(i.e., silences, reduces, or inhibits) expression of a target gene 
(i.e., by mediating the degradation of mRNAs which are 
complementary to the sequence of the interfering RNA) when 
the interfering RNA is in the same cell as the target gene. 65 
siRNA thus refers to the double stranded RNA formed by two 
complementary strands or by a single, self-complementary 
The active agent is contained substantially within the nano-
gel. The active agent may be loaded into the nano gel by many 
methods know in the art including, but not limited to, swell-
ing, emulsion, solvent evaporation, or in situ synthesis of the 
nano gel in the presence of the active agent. One of ordinary 
skill in the art would realize that the method for loading an 
active agent into a nano gel may depend upon several factors, 
such as polymeric composition of the nanogel, the composi-
tion of the active agent, and the composition of solvent or 
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carrier in which the active agent is mixed, among others. In an 
exemplary embodiment of the present invention, an active 
agent is loaded into a nanogel by swelling of the nanogel. 
Regardless of the method of loading, the active agent is 
retained in the nanogel through non-covalent interaction 
between the active agent and the nanogel. These non-covalent 
interactions may include ionic bonds, hydrophobic interac-
tions, hydrogen bonding, Van de Waals forces, Coulombic 
interactions, and the like. 
A nanogel-based delivery system may further comprise a 
targeting moiety. As used herein, the term "targeting moiety" 
refers to a substance associated with the crosslinked polymer 
shell that enhances binding, transport, accumulation, resi-
dence time, bioavailability, or modifies biological activity of 
the nanogels or its associated active agent in a cell or in the 
body of a subject. 
The targeting moiety can include, but is not limited to, an 
organic or inorganic molecule, peptide, peptide mimetic, pro-
teins, antibodies, growth factors, enzymes, lectins, antigens 
or immunogens, viruses, viral vectors, receptors, ligands 
(e.g., folic acid), toxins, polynucleotides, oligonucleotides or 
aptamers, nucleotides, carbohydrates, sugars, lipids, gly-
colipids, nucleoproteins, glycoproteins, lipoproteins, ste-
roids, hormones, growth factors, chemoattractants, cytok-
ines, chemokines, a drug, among others. 
In an exemplary embodiment of the present invention, the 
targeting moiety enhances binding, transport, accumulation, 
residence time, bioavailability, or modifies biological activity 
of the nanogels or active agents in a neoplastic cell or in the 
body of a subject having a neoplastic disease. Thus, the tar-
geting moiety can have specificity for cellular receptors asso-
ciated with neoplastic disease. For example, the targeting 
moiety can have specificity for the erythropoietin-producing 
hepatocellular (Eph) A2 receptor. In an exemplary embodi-
ment of the present invention, the targeting moiety comprises 
a peptide having the amino acid sequence YSAYPDS-
VPMMSC (SEQ ID NO 1 ), referred to herein as the "YSA 
peptide." The YSA peptide mimics the ligand, ephrin-Al, 
which binds to the EphA2 receptor. 
The targeting moiety can be coupled to the nanogel through 
the functionalization agent of the crosslinked polymeric 
shell. One of ordinary skill in the art would realize that selec-
tion of the targeting moiety may influence the selection of a 
functionalization agent as the method of coupling the target-
ing moiety to the crosslinked polymeric shell via the func-
tionalization agent may depend on the chemical composition 
of the functionalization agent. For example, in embodiments 
of the present invention comprising the YSA peptide targeting 
moiety, the YSA peptide may be coupled to the crosslinked 
polymeric shell by EDC coupling of E-maleimidocaproic acid 
to the primary amine of aminopropylmethacryamide in the 
crosslinked polymeric shell. As a result of coupling the tar-
geting moiety to the crosslinked polymeric shell of the nano-
gel through the functionalization agent, the targeting moiety 
is displayed on at least a portion of the crosslinked polymeric 
shell. 
An aspect of the present invention comprises a method of 
delivering an active agent into a cell, the method comprising: 
contacting a nanogel with a cell, the nanogel comprising a 
crosslinked polymer particle and an active agent contained 
substantially within the nanogel, wherein the active agent is 
non-covalently associated with the nano gel; and delivering an 
active agent to the cell. 
Although not wishing to be bound by any particular theory, 
it is currently believed that contacting and delivering an active 
agent to a cell occurs through receptor-mediated endocytosis. 
In one embodiment of the present invention, the nanogel 
10 
recognizes and binds a receptor on a cell surface. In an exem-
plary embodiment of the present invention, recognition and 
binding of a cell surface receptor is mediated by the targeting 
moiety associated with the crosslinked polymeric shell of the 
nanogel. Thus, the nanogel and its associated targeting moi-
ety participate in a cell surface binding event, which is the 
initiating step to the cellular cascade associated withreceptor-
mediated endocytosis. The term "receptor-mediated endocy-
tosis" generally describes a mechanism characterized by the 
10 binding of a ligand to a receptor disposed on the surface of a 
cell, where the receptor-bound ligand is internalized within a 
cell. Upon endocytosis of the nanogel, it is believed that the 
nanogel can escape the endosome and enter the cytosol to 
deliver the active agent by way of passive diffusion. Endoso-
15 ma! escape of the nanogels of the present invention appears to 
be an intrinsic property of the nano gel as not other substances 
are needed to facilitate endosomal escape of the nanogel and 
entry into the cytosol. 
In an exemplary embodiment of a method for delivering an 
20 active agent to a cell, the active agent can comprise a siRNA. 
In such embodiments, the method for delivering an active 
agent to a cell can further comprise reducing expression of a 
target gene, wherein the siRNA has substantial sequence 
identity to the target gene. As used herein, the term "reducing 
25 expression of a target gene" refers to the ability of a siRNA to 
silence, reduce, or inhibit expression of a target gene. To 
determine extent of the reduction of expression of a target 
gene, examination of protein or mRNA levels associated with 
the target gene can be performed using techniques known to 
30 one of ordinary skill in the art, such as northern blots, Western 
blots, RTPCR, ELISA, and immunoprecipitation, among oth-
ers. According to the embodiments of the present invention, 
silencing, inhibition, or reduction of expression of a target 
gene is achieved when the expression of the target gene is 
35 reduced about 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 
55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, or 10% as 
compared to a cell or organism not exposed to the siRNA. 
In one embodiment of a method for delivering an active 
agent to a cell, the nanogel can further comprise a targeting 
40 moiety and crosslinked polymer shell comprising a function-
alization agent, the crosslinked polymer shell disposed sub-
stantially around the crosslinked polymer particle, wherein 
the targeting moiety is attached to the crosslinked polymer 
shell through the functionalization agent, and wherein the 
45 targeting moiety is displayed on at least a portion of the 
crosslinked polymer shell. In an exemplary embodiment, this 
method can further comprise reducing expression of a target 
gene, wherein the targeting moiety comprises a peptide hav-
ing the amino acid sequence YSAYPDSVPMMSC (SEQ ID 
50 NO 1 ), and wherein the active agent is a siRNA having sub-
stantial sequence identity to the target gene, and wherein the 
target gene encodes epidermal growth factor receptor. 
Another aspect of the present invention comprises a 
method for treating neoplastic disease comprising: adminis-
55 tering to a subject having neoplastic disease an effective 
amount of a nano gel comprising a crosslinked polymer par-
ticle; a crosslinked polymer shell comprising a functionaliza-
tion agent, wherein the crosslinked polymer shell is disposed 
substantially around the crosslinked polymer particle; a tar-
60 geting moiety, wherein the targeting moiety is attached to the 
crosslinked polymer shell through the functionalization 
agent, and wherein the targeting moiety is displayed on at 
least a portion of the crosslinked polymer shell; and an active 
agent contained substantially within the nanogel, wherein the 
65 active agent is non-covalently associated with the nanogel. 
The terms "subject," "individual" or "patient" are used 
interchangeably herein, and refers to a vertebrate, preferably 
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a mammal, and more preferably a human. Mammals include, 
but are not limited to, primates, humans, cows, dogs, mice, 
rabbits, swine, rats, guinea pigs and equine. Tissues and cells 
are also encompassed by this terminology. 
12 
product relevant to neoplastic disease including but not lim-
ited to an anti-apoptotic molecule, a growth factor, a growth 
factor receptor, a mitotic spindle protein, a cell cycle protein, 
an angiogenic factor, an oncogene, an intracellular signal 
transducer, a molecular chaperone, among others. In an 
exemplary embodiment of the present invention, the target 
gene encodes epidermal growth factor receptor. 
In yet another embodiment of a method of treating a neo-
plastic disease, the method can further comprising increasing 
Systems and methods of the present invention contemplate 
treatment of a subject having neoplastic disease. Systems and 
methods of the present invention comprise administering an 
effective amount of a compound or composition to treat, 
ameliorate, or prevent neoplastic diseases in a subject. More 
specifically, systems and methods of the present invention 
comprise treatment of a human having neoplastic disease. 
Neoplastic disease may occur in many organs or tissues, 
including, but not limited to, bone, brain breast, cervix, colon, 
endometrium, esophagus, eye, gallbladder, kidney, liver, 
lung, lymphoid, mucosa!, neuronal, ovary, pancreas, prostate, 
rectal, skin, stomach, and/or testicle, among others. The term 
"neoplastic disease" is intended to refer to hyperplasia, 
tumors, tumorigenesis, cancer, metastasis, cells that have 
uncontrolled growth, and the like. The systems and methods 
10 sensitivity of the subject to a chemotherapeutic agent. The 
chemotherapeutic agents can be one or more of many chemo-
therapeutic agents known in the art including, but not limited 
to taxane chemotherapy, such as paclitaxel and docetaxel. As 
used herein "increased sensitivity to a chemotherapeutic 
15 agent" refers to an increase in susceptibility (or conversely a 
reduction in chemoresistance) of a neoplastic-related pathol-
ogy to a chemotherapeutic agent upon exposure to the siRNA 
as compared to the level of sensitivity to a chemotherapeutic 
of the present invention may be used in combination with 20 
other treatments for neoplastic disease know in the art, 
including, but not limited to, surgery, radiation therapy, che-
motherapy, and immunotherapy, among others. 
agent in the absence of the siRNA. 
It must be noted that, as used in this specification and the 
appended claims, the singular forms "a," "an," and "the" 
include plural referents unless the context clearly dictates 
otherwise. 
Embodiments of the methods of treating neoplastic disease 
of the present invention comprise administering an effective 
amount of a nanogel. Administration of the nanogels may be 
performed by many known routes of administration, includ-
ing, but not limited to, topical administration, oral adminis-
tration, enteral administration, intratumoral administration, 
parenteral administration (e.g., epifascial, intraarterial, intra-
capsular, intracardiac, intracutaneous, intradermal, intramus-
cular, intraorbital, intraosseous, intraperitoneal, intraspinal, 
intrasternal, intravascular, intravenous, intravesical, paren-
chymatous, or subcutaneous administration), among others. 
All patents, patent applications and references included 
25 herein are specifically incorporated by reference in their 
entireties. 
Throughout this description, various components may be 
identified as having specific values or parameters, however, 
these items are provided as exemplary embodiments. Indeed, 
30 the exemplary embodiments do not limit the various aspects 
and concepts of the present invention as many comparable 
parameters, sizes, ranges, and/or values may be implemented. 
It should be understood, of course, that the foregoing relates 
only to exemplary embodiments of the present invention and 
A "therapeutically effective amount" or "an effective 
amount" in the context of the present invention is considered 
35 that numerous modifications or alterations may suggest them-
selves to those skilled in the art without departing from the 
spirit and the scope of the invention as set forth in this disclo-
sure. 
to be any quantity of the active agent, which, when adminis-
tered to a subject, causes prevention, reduction, remission, 
regression, or elimination of a neoplastic-related pathology. 
For example, in the context of cancer, "an effective amount" 40 
is considered to be any quantity of the one or more active 
agents, which, when administered to a subject causes preven-
tion, reduction, remission, regression, or elimination oftum-
origenesis and/or metastasis. 
The present invention is further illustrated by way of the 
examples contained herein, which are provided for clarity of 
understanding. The exemplary embodiments should not to be 
construed in any way as imposing limitations upon the scope 
thereof. On the contrary, it is to be clearly understood that 
resort may be had to various other embodiments, modifica-
tions, and equivalents thereof which, after reading the 
description herein, may suggest themselves to those skilled in 
the art without departing from the spirit of the present inven-
tion and/or the scope of the appended claims. 
Therefore, while embodiments of this invention have been 
In embodiments of the present invention where the active 45 
agent is a siRNA, an "effective amount" or "therapeutically 
effective amount" of a siRNA can further include an amount 
sufficient to produce the desired effect, e.g., a decrease in the 
expression of a target sequence in comparison to the normal 
expression level detected in the absence of the siRNA. 
The dosage of the active agent will depend on the condition 
being treated and the extent of the neoplastic disease, the 
particular active agent, route of administration, and other 
clinical factors such as weight and condition of the subject. 
siRNA may be provided in dosages ranging from about 0.001 55 
µg/kg/day to about 1,000 mg/kg/day. Depending on the route 
50 described in detail with particular reference to exemplary 
embodiments, those skilled in the art will understand that 
variations and modifications can be effected within the scope 
of the invention as defined in the appended claims. Accord-
of administration, the active agent administered and the tox-
icity associated with the nano gel-active agent system, a pref-
erable dosage would be one that would yield an adequate 
blood level or tissue fluid level in the subject that would 60 
effectively cause prevention, reduction, remission, regres-
sion, or elimination of a neoplastic-related pathology. 
In an exemplary embodiment of the present invention 
where the active agent is siRNA, a method of treating neo-
plastic disease can further comprise reducing expression of a 65 
target gene, wherein the siRNA has substantial sequence 
identity to the target gene. The target gen can encode a gene 
ingly, the scope of the various embodiments of the present 
invention should not be limited to the above discussed 
embodiments, and should only be defined by the following 
claims and all equivalents. 
EXAMPLES 
Example 1 
Peptide-Fiunctionalized Nanogels for Targeted 
siRNA Delivery 
The present Example is directed to drug delivery systems 
and methods that employ the synthetic hydrogel nanoparticle 
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(nanogel). Nanogels possess a high degree of porosity, per-
mitting a high payload capacity and can also be selectively 
surface functionalized to enable tumor-specific targeting. 
Thus, we have developed straightforward, scalable syntheses 
of surface-functionalized, -100-nm diameter, core/shell 5 
nanogels composed of poly(N-isopropylmethacrylamide) 
(pNIPMAm), an amphiphilic polymer that is strongly 
hydrated at physiological temperature and is likely therefore 
to resist protein adsorption relative to more hydrophobic car-
riers. This polymer has also garnered interest due to its dra- 10 
matic thermoresponsivity; it undergoes an entropically driven 
coil-to-globule (swollen-to-collapsed) transition at -43° C., 
which may have utility for thermally-triggered delivery. 
However, in the present Example, this thermoresponsivity is 
only used to enable the synthesis of monodispersed core/shell 15 
nanogels via precipitation polymerization, as we have dis-
cussed previously in Jones, C. D., and Lyon, L. A. (2000) 
Synthesis and Characterization of Multiresponsive Core-
Shell Micro gels. Macromolecules 33, 8301-8306, and Black-
bum, W. H., and Lyon, L.A. (2008) Size-controlled synthesis 20 
of monodisperse core/shell nanogels. Colloid Polym. Sci. 
286, 563-569. 
The core/shell pNIPMAm nanogel construct used to 
encapsulate and deliver siRNA to ovarian cancer cells is 
illustrated in FIG. 1. A 12 amino acid peptide (YSAYPDS- 25 
VPMMS or "YSA") (SEQ ID NO 1) was coupled to surface 
of -100-nm diameter core/shell nanogels to permit cell-spe-
cific targeting and subsequent delivery of high concentrations 
of siRNA to the target cells. The YSA peptide mimics the 
ligand ephrin-Al, which binds to the erythropoietin-produc- 30 
ing hepatocellular (Eph) A2 receptor. In addition to specific 
expression in neovasculature, EphA2 is highly expressed by a 
number of tumor cells including those derived from ovarian, 
prostate, breast, and colon cancers, making it an excellent 
target for tumor-specific delivery. Thus, we demonstrate 35 
herein that pNIPMAm nanogels have a high loading capacity 
for siRNA, and that these nanogels are delivered to the cyto-
plasm of ovarian cancer cells via ligand-receptor binding 
mediated endocytosis. Importantly, cytotoxicity was not 
observed to arise from the nanocarrier, suggesting that this 40 
approach could be a highly efficacious one. In addition, deliv-
ery of siRNA to cells in culture can be performed in the 
presence of serum suggesting that nano gels may be of par-
ticular advantage for in vivo delivery. 
Material and Methods. All materials were purchased from 45 
Sigma-Aldrich (St Louis, Mo.) and used as received unless 
otherwise noted. 
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make the final concentration of APS in the reaction -8 mM. 
The solution turned turbid, indicating successful initiation. 
The reaction was allowed to continue for 4 h under an N2 
blanket. After synthesis, the solution was filtered through 
Whatman filter paper to remove a small amount of coagulum. 
Nanogel shell synthesis. The core nanogels described 
above were used as seeds for the addition of a hydrogel shell 
in a seeded precipitation polymerization scheme. Briefly, 10 
mL of the core nanogel solution and 0.0577 g SDS were first 
added to a three-neck round-bottom flask and heated under 
N2 gas to 70° C. A 50 mM monomer solution with molar 
ratios of97.5% NIPMAm, 2% BIS, and 0.5% aminopropyl-
methacrylamide (APMA, Polysciences, Warrington, Pa.)was 
prepared in 39.5 mL of dH20. The solution was added to the 
three-neck round-bottom flask, and the temperature was sta-
bilized at 70° C. while continuously stirring. The reaction was 
initiated by a 0.5 mL aliquot of 0.05 MAPS. The reaction 
proceeded for 4 h under N2 gas. Following the synthesis, the 
solution was filtered through Whatman filter paper, and the 
nanogels were purified by centrifugation followed by resus-
pension in dH20. 
Nanogel characterization. Multi-angle laser light scatter-
ing (MALLS) (Wyatt Technology Corporation, Santa Bar-
bara, Calif.) detection following asymmetric field flow frac-
tionation (AFFF) was used to determine the distribution of 
z-average radii (R2 ) for all nanogels. For all separations, a 
cross-flow of 0.30 mL/min was used with a channel flow of 
1.0 mL/min The MALLS detector is equipped with a Peltier 
device to maintain a flow cell temperature of 25° C. and 
collects scattered light from 16 different fixed angles to deter-
mine the R2 of the nano gels. By measuring R2 as a function of 
elution time, we constructed a chromatogram that permits the 
determination of the weight fraction of nano gels as a function 
of radius, thereby providing a sample polydispersity. ASTRA 
5.1.5.0 software was used to determine R2 values using the 
Debye fit method. The core/shell nanogels synthesized using 
the methods described above were determined to have R2 
values of -54 nm with size polydispersities of <l 0 as repre-
sentative AFFF /MALLS data are shown in FIG. 2. 
Characterization of the refractive increment (dn/dc) of 
nanogels was performed to determine particle molecular 
weight by static light scattering. Differential refractive index 
analysis (dRI, OptiLab rEX, Wyatt Technologies, Inc.) was 
performed in batch mode. To ensure accurate data, the refrac-
tive index was calibrated prior to each measurement using 
sodium chloride concentrations ranging from 0.1 mg/mL to 
15.0 mg/mL. All nano gel dilutions were prepared in dust-free 
vials, which were rinsed sequentially with deionized water, 
absolute ethanol, and HPLC-grade acetone. Nanogels were 
Nanogel core synthesis. Nanogel core particles were syn-
thesized by free-radical precipitation polymerization, as dis-
cussed in Blackbum, W. H., and Lyon, L. A. (2008) Size-
controlled synthesis of monodisperse core/shell nanogels. 
ColloidPolym. Sci. 286, 563-569. The use of thermally phase 
separating polymers enables the use of precipitation polymer-
ization for the synthesis of highly monodispersed nanogels. 
The molar composition was 98% N-isopropylmethacryla-
mide (NIPMAm), 2% N,N'-methylenebis(acrylamide) (BIS), 
with a total monomer concentration of 140 mM. The solution 
also contained a small amount (-0.1 mM) ofacrylamidofluo-
rescein (AFA) to render the nanogels fluorescent for visual-
ization via confocal microscopy. In a typical synthesis, 100 
mL of a filtered, aqueous solution of NIPMAm, BIS, and 
sodium dodecyl sulfate (SDS, 8 mM total concentration) was 
added to the reaction flask, which was then heated to 70° C. 
The solution was purged with N2 gas and stirred vigorously 
until the temperature remained stable. The AFA was added, 
and after 10 minutes the reaction was initiated by the addition 
of a 1 mL solution of800 mM ammonium persulfate (APS) to 
50 resuspended in distilled, deionized water over a concentration 
range from 2.5xl0-6 g/ml to 3.75xl0-4 g/mL. The use of 
MALLS in conjunction with the rEX differential refractome-
ter permitted the measurement of the z-average molecular 
mass (M2 ) from the determined dn/dc values and the angle 
55 dependent light scattering data. 
YSA synthesis. The YSA peptide (YSAYPDSVPMMSC) 
(SEQ ID NO 1 )was synthesized using standard Fmoc chem-
istry as described in Clark, K. D., Volkman, B. F., Thoetkiat-
tikul, H., King, D., Hayakawa, Y., and Strand, M. R. (2001) 
60 Alanine-scanning mutagenesis of plasmatocyte spreading 
peptide identifies critical residues for biological activity. J. 
Biol. Chem. 276, 18491-6. Following synthesis, the peptide 
was cleaved from the resin and deprotected for 4 h in reagent 
K after air-drying. The peptide was purified using a series of 
65 5 mL injections onto a preparatory HPLC colunm (10-m; 
particle size, 21.2 mm 25 cm, JupiterC18; Phenomenex Inc., 
Torrance, Calif.) using HPLC-grade H2 0 and a linear gradi-
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tioning to determine the maximum loading level. To deter-
mine the rate of siRNA release from nanogels loaded in this 
fashion, a mixture of oligonucleotide was prepared contain-
ing 0.250 mL of20 µM siGLO red transfection indicator and 
1.00 mL of 20 µM siGENOME Lamin A/C control siRNA 
(Dharmacon, USA). Particles were resuspended in this mix-
ture at a concentration of 4 mg per 250 µL siRNA solution. 
This concentration of particles is near the solubility limit for 
the nanogels in PBS, ensuring a high degree of solvent and 
ent of acetonitrile (0-70 min, 10-80%) at 5 mL per min Both 
the acetonitrile and H20 contained 0.05% trifluoroacetic 
acid. The desired peak was identified by matrix-assisted laser 
desorption ionization time-of-flight mass spectrometry, and 
the peaks from multiple runs were pooled, lyophilized, and 
stored at 4° C. in solid form. A scrambled form (SCR) of the 
YSA peptide (DYPSMAMYSPSVC) (SEQ ID NO 2) was 
also synthesized via this method for use as a control. On other 
occasions, the YSA and SCR peptides were purchased from 
GenScript Corp (Piscataway, N.J.). 
Peptide conjugation. In this sExample, a maleimide-func-
tionalized nanogel was produced through the EDC coupling 
10 solute uptake into the hydrogel network. The particles were 
allowed to resuspend for 12 hours at room temperature while 
shaking. 
of E-maleimidocaproic acid (EMCA) to the primary amines The encapsulation efficiency was determined via ultra-
centrifugation of the nano gel loading solution and measure-in the shell of the nanoparticle. As described in the nano gel 
shell synthesis, primary amines were introduced through the 
copolymerization of APMA (0.5% molar ratio). Given that 
APMA is efficiently incorporated at these low molar ratios, 
the amine equivalents available for bioconjugation can be 
estimated (-2.2xl o-6 amines per 88.3 mg oflyophilized par-
ticles). From this estimate, peptide coupling was performed 
by introducing YSA peptide in a 1: 1 molar ratio with amine 
(YSA molecular weight=1450.66 g/mol). The YSA peptide 
was then conjugated to the nanogels via maleimide coupling 
15 ment of supernatant siRNA concentration by UV-vis spec-
troscopy (Shimadzu UV-1601). The moles of siRNA in the 
loading solution (msiRNA. Loading) and in the supernatant 
(msiRNA. supernatant) were determined via interpolation from a 
separately constructed standard curve of absorbance vs. con-
to the cysteine residue on the C-terminal end of the peptides. 
20 centration (R2>0.99). The encapsulation efficiency (EE) of 
the system could then be calculated through analysis of the 
amount of siRNA in the loading solution and the remaining 
moles of siRNA in the supernatant after nanogel swelling was 
complete, as illustrated by Equation 1 and in similar encap-
25 sulation experiments. First, 88.3 mg of nano gels (-2.2xl0-6 amine equivalents) 
was resuspended in 35.0 mL of pH 6.0 MES buffer and 
allowed to shake for 2 hours. A second solution was prepared 
where 4.4xl o-6 moles (0.68 mg) ofl-ethyl-3-methyl-(3-dim-
ethylaminopropyl) carbodiimide (EDC, Pierce, Rockford, 
Ill.), 4.4xl0-6 moles (0.96 mg) N-hydroxysulfosuccinimide 30 
(NHSS) and 2.2xl0-6 moles (0.46 mg) ofEMCA were dis-
solved in 3.0 mL of pH 6.0 MES buffer. This solution was 
reacted for 30 min at room temperature to activate the EMCA 
acid groups, which permits amide coupling to take place 
between the EMCA acid groups and the amines on the nano- 35 
gel surface. This activated EMCA solution was then added to 
the nano gel solution and reacted for 2 hon a shaker table. The 
nanogels were centrifuged 3 times to remove any unreacted 
material, with resuspension in pH 6.0 MES buffer following 
each centrifugation. Finally, 3.2 mg of the appropriate peptide 40 
was added to the activated nanogels and reacted overnight. 
Peptide-functionalized nano gels were purified by centrifuga-
tion and resuspended in distilled, deionized water. 
The number of bioconjugated YSA targeting peptides per 
particle was estimated by considering the number of primary 45 
amines available for conjugation and the number density of 
nanogels used during bioconjugation (as measured by static 
light scattering). Through differential refractometry, the 
nanogel refractive increment was determined to be 
0.176±0.002 mL/g Measurement of z-average molecular 50 
weight through multi-angle static light scattering provided 
the z-average mass of non-conjugated particles, M2 =2.19x 
107 g/mol (1 ° De bye fitting, 0.1 % fit error). Thus, a total mass 
of88.3 mg oflyophilized particles used during conjugation is 
equivalent to 2.43xl015 particles. Assuming a 50% peptide 55 
conjugation efficiency and 2.2xl o-6 amine equivalents avail-
able for bioconjugation, a conservative estimate of peptide 
density is -225 YSA peptides/particle. 
In vitro siRNA encapsulation and release. Our group 
employs a "breathing-in" method for the encapsulation of 60 
various macromolecules within nanogels. In a typical 
method, lyophilized nanogels are resuspended in an aqueous 
solution containing the macromolecule to be loaded. Impor-
tantly, this is done using a loading solution volume that is 
almost completely imbibed by the swelling nanogels. In this 65 
fashion, the hydrogel network imbibes the payload with high 
efficiency and without relying on simple equilibrium parti-
EE = msiRNA,Loading - msiRNA,Supematant x 100 
msiRNA,Loading 
(1) 
The release of solutes from nanogels was performed in 10% 
serum to simulate physiological conditions. Release experi-
ments were performed by dispersing 200 µL of loaded nano-
gels in 2.20 mL of0.01 M phosphate buffered saline contain-
ing 10% fetal bovine serum (equilibrated at 3 7° C.) in 3 .2 mL 
polycarbonate centrifuge tubes (Beckman Coulter, USA). 
The nanogel suspension was allowed to incubate at 37° C. 
while shaking. At specific time points, the tubes were centri-
fuged for 90 mM at 687 OOOxg (at 37° C.), and an aliquot of 
supernatant (0.75 mL) was removed for UV-vis analysis. This 
volume was replaced with fresh buffer. Upon centrifugation, 
the gel pellet had a homogenously distributed bright pink 
color, indicating significant retention of siRNA throughout 
the experiment. The cumulative siRNA released was calcu-
lated by calculating the total moles detected in the superna-
tant as a function of time, as described in Equation 2. 
Cumulative siRNA Released = mroTALsiRNA,Supernatant x 100 
msiRNA,Loading 
(2) 
All release studies were performed in triplicate for statis-
tical analysis, using identical nanogel loading and release 
conditions. 
Zeta-potential determination. Excluding the 0.5 mo! % 
APMA copolymerized into the shell of our nano gel particles, 
the nanogels are composed of largely non-ionic monomers. 
To confirm their suspected electroneutrality, which should be 
critical for reducing non-specific cell and protein interac-
tions, the zeta-potential of both YSA-conjugated and non-
conjugated core/shell nanogels were measured (Zeta-Sizer 
Nano, Malvern, U.K.). All nanoparticles used in this investi-
gation demonstrated zeta-potential values <+0.300 m V, sug-
gesting that they are only weakly charged and should there-
fore not interact strongly with serum proteins or cell surfaces 
via Coulombic forces. 
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Cell culture. Hey cells were provided by Gordon W. Mills, 
Department of Molecular Therapeutics, the University of 
Texas, M.D. Anderson Cancer Center. Hey cells were cul-
tured in RPMI 1640 (Mediatech, Manassas, Va.) supple-
mented with 10% v /v heat-inactivated fetal calf serum (Invit- 5 
rogen), 2 mM L-glutamine (Mediatech), 10 mM HEPES 
buffer (Mediatech), penicillin (100 U/ml), and streptomycin 
(100 µg/mL). The BG-1 cell line was provided by Julie M. 
Hall and Kenneth S. Korach, Receptor Biology Section, 
Laboratory of Reproductive and Developmental Toxicology, 10 
National Institute of Environmental Health Sciences, NIH, 
Division oflntramural Research, Environmental Disease and 
Medicine Program, Research Triangle Park, N.C. BG-1 cells 
were propagated in DMEM:F12/50:50 (Mediatech) supple-
mented with 10% v/v heat-inactivated fetal calf serum, peni- 15 
cillin, and streptomycin. 
siRNA encapsulation for cell studies. Using the "breath-
ing-in" method for encapsulation (as described above), dried 
nanogels were reswollen in the presence of the siRNA, 
thereby imbibing the solute within the hydrogel network. In a 20 
typical procedure for in vitro cell delivery, a 20 µM solution 
(250 µL) of a fluorescent siRNA transfection indicator, 
siGLO (Dharmacon), or EGFR siRNA (Dharmacon, Lafay-
ette, Colo.) was prepared in phosphate buffered saline (PBS). 
Lyophilized nano gels were dissolved in the siRNA solution at 25 
a concentration of 4 mg in 250 µL and allowed to shake 
overnight at room temperature. Importantly, this nano gel con-
centration results in nearly all of the solvent being taken up by 
the nanogels. This volume-filling approach ensures a maxi-
mal uptake of siRNA within the nanogels. After shaking, the 30 
nanogels were centrifuged to remove any free siRNA and 
resuspended in PBS. A standard curve for increasing concen-
trations of siRNA was made by measuring the absorbance at 
260 nm using a Shimadzu UV 1601 spectrophotometer. After 
siRNA was encapsulated in the nanogels, they were centri- 35 
fuged, and the absorbance of the supernatant was measured to 
determine the amount of incorporated siRNA. 
Cell transfection using nanogels. Hey or BG-1 cells were 
plated onto an 8-well chamber slide (5xl03 cells/well), and 
the cells allowed to adhere overnight at 37° C. in a 5% C02 40 
atmosphere. After washing the wells with PBS and replacing 
the media, siGLO-loaded/YSA-conjugated nanogels, 
unloadedYSA-conjugated nanogels, pNIPMAnl nano gels, or 
siGLO only were added to wells. Cells were incubated in each 
case for 4 h. In experiments where preincubation of ephrin- 45 
Al was used to initiate internalization and degradation of 
EphA2, ephrin-Al was added to the media at a final concen-
tration of the ligand of 2 µg/mL. After incubation, the cells 
were washed with PBS, and the medium replaced. For fixa-
tion prior to confocal imaging, the cells were incubated with 50 
2% (v/v) paraformaldehyde for 30 min 
Immunoblotting. Hey cells were plated into 6-well plates 
(5xl05/well) and allowed to adhere overnight at 37° C., 5% 
C02 . The cells were lysed with 100 µL oflysis buffer (50 mM 
Tris-HCl, pH 7.5, 150 mM NaCl, 2 mM EDTA (Fisher), 2 55 
mM EGTA (Fisher), 1 mM sodium orthovanadate, 2.5 mM 
sodium pyrophosphate, 1 mM ~-gycerolphosphate, 1 mM 
phenylmethanesulfonyl fluoride, 10 µg/mL aprotinin, 10 
µg/mL leupeptin, 1 % Triton X-100, and 5% glycerol), and the 
cell lysates sonicated four times for five seconds each. The 60 
lysates were cleared by centrifugation at 11,000xg rcffor 15 
mM at 4 ° C. Cell lysates were prepared for analysis by the 
addition of an equal volume of Laemmli 2x sample buffer. 
The samples were heated to 95° C. for 5 mM to denature the 
proteins. The proteins were separated on a 10% SDS-PAGE 65 
gel and transferred onto nitrocellulose. The blots were 
blocked with either 5% nonfat dry milk (NFDM) or 5% 
18 
bovine serum albumin (BSA) in 10 mM Tris-buffered saline, 
pH 7.5 plus 1% Tween20 (TBST, BioRad) for 1 hour at room 
temperature. The blots were probed with anti-EGFR antibody 
(Cell Signaling, Danvers, Mass.; cat. no. 4405) or with a 
~-actin antibody (Millipore, Billerica, Mass.; Mab1501) 
diluted in 5% NFDM or 5% BSA overnight, with shaking at 
4° C. For EphA2 detection, the blots were probed with an 
anti-EphA2 polyclonal antibody (Santa Cruz Biotechnology, 
Santa Cruz, Calif.; sc-294). The blots were washed three 
times with TBST and probed with goat anti-rabbit IgG (Santa 
Cruz, sc-2004) or with goat anti-mouse IgG (Santa Cruz, 
sc-2005) linked to horseradish peroxidase (HRP). Bands 
were visualized on film (Pierce) using the ECL reagent, 
SuperSignal West Pico™ (Pierce). 
Confocal microscopy. A Zeiss LSM510 confocal micro-
scope was used to take cell images. Cells were incubated with 
nanogels for 4 h. After 4 h, the cells were washed and then 
fixed on the slide. AnAr+ laser was used to excite the AFA-
labelednanogels, whereas a HeNe laser was used to excite the 
fluorescently labeled siGLO. LSM510 software was used to 
view the images. 
Flow cytometry. Hey cells were plated at 2.5xl05 cells/ 
well in a 12-well, cell culture plate. Cells were allowed to 
adhere overnight in an incubator at 37° C. in a 5% C02 
atmosphere. Cells were washed, and fresh medium was added 
containing YSA-pNIPMAnl or SCR-pNIPMAnl nanogels at 
a concentration of 0.8 mg/mL and incubated for four hours. 
Following incubation, the cells were washed with PBS and 
removed from the plate by Trypsin-EDTA treatment. The 
cells were washed with PBS and fixed with 2% (v/v) 
paraformaldehyde. Cells were analyzed using a LSR Flow 
Cytometer (BD Biosciences). Data analysis was carried out 
using Flow Jo software. 
Toxicity Studies-Trypan blue exclusion assay. Hey cells 
were plated onto an 8-well chamber slide (lxl04 cells/well) 
and allowed to adhere overnight at 37° C. and 5% C02 . The 
media was removed, the wells washed with PBS, and the 
medium replaced. PNIPMAnl nanogels, YSA-conjugated 
nanogels, and SCR-conjugated nanogels were added to cells 
and incubated for 72 h. Untreated cells were used as controls. 
After 72 h, the cells washed with PBS, and a 1: 1 solution of 
trypan blue was added to each well. After 1 min, the trypan 
blue was removed, the cells were washed with PBS, fixed 
with 2% (v/v) paraformaldehyde, and air dried. Each well was 
then viewed via bright field microscopy to determine the 
number of stained (dead) versus unstained cells. Five fields 
were viewed for each treatment. 
Toxicity Studies-Tax 8 assay. Hey cells were plated onto 
96-well plates (1xl04 cells/well) and allowed to adhere over-
night at 37° C. and 5% C02 . The media was removed, and the 
cells were washed with PBS followed by replacement of the 
medium. Cells incubated with EGFR siRNA-loaded YSA-
labeled nanogels, unloaded YSA-labeled pNIPMAnl nano-
gels, unlabeled pNIPMAnl, or YSA peptide alone were tested 
using this assay. The cells were incubated under all conditions 
for 4 h. The cells were then washed with PBS, the medium 
replaced, and the cells incubated for an additional 72 h in 
medium. The Tox 8 reagent (Sigma) was added to the cells 
according to the manufacturer's instructions. The absorbance 
at 600 nm was read after 1 hour, and the extent of cellular 
viability/proliferation determined 
Results. The nanogels described in this contribution were 
developed around two main design criteria, as depicted in 
FIG. 1. For this application, both peptide-based targeting of 
ovarian cancer and efficient encapsulation and delivery of 
RNA inhibitors (RNAi's) are required. The core/shell nano-
gels synthesized using the methods described above were 
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determined to have R2 values of-54 nm with size polydisper-
sities of <l 0%, as described previously. Representative 
AFFF/MALLS chromatograms for both the core and core/ 
shell nanogels are shown in FIG. 2. To determine the times-
cale for retention of siRNA within the pNIPMAm nano gels, 
siRNA leakage was investigated using simulated physiologi-
cal conditions. As described above, nanogels were loaded 
using a model mixture of siRNA, containing both the siGLO 
red transfection indicator and the siGENOME Lamin control. 
The nanogel was observed to encapsulate the siRNA with 
high efficiency (93±1%), which is equivalent to a loading 
level of 1.6 wt% or 16 µg siRNA/mg of nano gels. As shown 
in FIG. 3, only -33% of the siRNA is observed to leak from 
the nanogels within the first 12 hours (67% retained). Indeed, 
this approximate level of retention persists out to 35 hours, 
suggesting very efficient entrapment of the siRNA within the 
nano gel network. Retention of this magnitude is promising 
for intravenous oligonucleotide delivery given previously 
determined timescales (-6 hours) for extravasation via the 
enhanced permeability and retention effect. 
To establish the efficacy of targeting in vitro, the uptake of 
nano gels by two ovarian cancer cell lines, Hey and BG-1, was 
determined We previously demonstrated high expression of 
EphA2 by Hey cells and low expression of the receptor by the 
BG-1 cell line. Because of these differences in EphA2 expres-
sion, we expected to see higher levels of nano gel uptake via 
receptor-mediated endocytosis with Hey cells as compared to 
BG-1 cells. Furthermore, we expected that the degree of 
siRNA delivery to those cells would be dependent on the cell 
type and the presence of the peptide ligand. To load siRNA 
into the nanocarrier, lyophilized nanogels were loaded with 
siGLO (a fluorescently-labeled siRNA delivery tracker) by 
reswelling them in a concentrated solution of the siRNA, as 
described above. To obtain a relative concentration of the 
siGLO taken up by the nanogels, absorbance measurements 
were compared to a standard curve of siGLO in solution 
(R2>0.99). We determined in a series of three trials that 
80-95% (by mass) of the siGLO was incorporated into the 
nano gels by this method, in agreement with the loading levels 
calculated in the release kinetics experiment described above. 
Following loading with siGLO, nanogels were incubated 
with either Hey (high EphA2 expression) or BG-1 (low 
EphA2 expression) cells in order to compare the levels of 
targeted uptake by ovarian cancer cells. Uptake of the nano-
gels into the cells was followed using a fluorescent tag (AFA) 
incorporated into the nanogel core as well as by the fluores-
cence of the siGLO. In previous studies, we determined that 
high levels of nanogel uptake by cells occurred after four 
hours. As a result, cells were incubated for four hours with 
siGLO-loaded/YSA-conjugated nanogels to monitor specific 
targeting to EphA2. Unloaded YSA-conjugated nanogels, 
non-targeted pNIPMAm nanogels, and siGLO only were 
used as controls, with identical 4-hour incubation times. In all 
experiments described in this Example, we maintained a con-
stant nanogel/cell ratio of 1 mg nanogels/5xl05 cells. For 
siRNA-loaded nanogels, this corresponds to 16.6 µg siRNA/ 
5xl 05 cells. After incubation, the cells were washed, and the 
slides fixed for confocal microscopy imaging. FIG. 4a shows 
that Hey cells targeted with YSA-conjugated nanogels have 
high levels of nanogel uptake as indicated by the presence of 
green fluorescence. At this time point, siGLO was retained at 
high levels within the internalized nanogels as indicated by 
the cell-localized red fluorescence. Merging of the two fluo-
rescence channels showed strong overlap, further indicating 
delivery of the siGLO by the nano gels into the Hey cells. Hey 
cells incubated with YSA-targeted but unloaded nanogels 
showed strong green fluorescence, indicating cell uptake. A 
20 
small amount of non-targeted uptake was observed for nano-
gels lacking the YSA peptide. Note that it was extremely 
difficult to find evidence of nonspecific uptake, and the fluo-
rescence shown in the figure represents the appearance of the 
5 rare uptake event observed, and does not represent the overall 
fluorescence from the entire population of cells. When Hey 
cells were incubated with siGLO alone, no cell-localized red 
fluorescence was detected; this is expected since RNA does 
not easily permeate the cell membrane in the absence of a 
10 carrier vehicle. 
Targeting experiments were also performed using low 
EphA2 expressing BG-1 cells (FIG. 4b ). Decreased levels of 
green fluorescence were observed in BG-1 cells when com-
pared to the fluorescence observed in the Hey cell cultures. 
15 The lower amount ofnanogel uptake by the BG-1 cells was 
most likely due to the reduced EphA2 receptor expression; we 
have demonstrated a -2.5-fold difference in EphA2 expres-
sion levels between these two cell lines. Control studies using 
non-targeted pNIPMAm nanogels or siGLO only showed no 
20 fluorescence in either the green or red fluorescent channels. 
These results indicate that the YSA peptide imparts targeting 
properties to the nanogels in the case of both the high (Hey) 
and low (BG-1) EphA2 expressing cells, and that the amount 
of nanogel uptake was dependent upon the level of EphA2 
25 receptor expression. These results also indicate that nonspe-
cific or non-targeted uptake of nanogels by cultured cells is 
low, and that the siRNA is unable to penetrate the cell mem-
brane in the absence of a carrier vehicle. Together, these initial 
results illustrate the promise of the targeted nano gel construct 
30 for targeted delivery of oligonucleotide cargo. 
To further establish the mechanism of nanogel targeting 
and uptake, we took advantage of the known receptor inter-
nalization properties of the EphA2 receptor. Specifically, it 
has been shown that binding of ephrin-Al, a ligand for 
35 EphA2, to EphA2 receptor causes internalization and degra-
dation of the receptor-ligand complex. FIG. 5 shows the 
results of studies wherein this receptor recycling process was 
used to establish the nanogel target by preincubating Hey 
cells with ephrin-Al before YSA-targeted nanogel incuba-
40 tion. We hypothesized that if uptake of nanogels is EphA2 
receptor-mediated, YSA-targeted uptake after cell exposure 
to ephrin-Al should be reduced, as the EphA2 receptor will 
be internalized and less available for binding to the nanogels. 
Hey cells were incubated overnight in an 8-well chamber 
45 slide. Two µg/mL of ephrin-Al were added, and the cells were 
incubated for 1 hour at 37° C. After ephrin-Al incubation, 
siGLO-loaded/YSA-conjugatednanogels were added to both 
ephrin-Al and control (PBS) treated wells. The cells were 
incubated for four hours, washed, and processed for imaging. 
50 FIG. 5 shows the nanogel uptake in Hey cells preincubated 
with ephrin-Al. Whereas these cells (top three panels) show 
some uptake of nanogels and encapsulated siGLO, the 
amount of uptake is greatly diminished compared with 
untreated cells (lower three panels). These results suggest that 
55 YSA-conjugated uptake by Hey cells is conducted to a large 
extent through EphA2, however, a small amount of uptake 
may occur through nonspecific mechanisms or via binding of 
YSA to other Eph receptors. This is not surprising, given the 
fact that ephrin and various small molecule ephrin mimics 
60 display binding affinities for multiple receptors of the Eph 
family. Flow cytometry was also used to establish the EphA2-
associated binding of the peptide-targeted nanogels. In this 
case, a scrambled (SCR) peptide sequence (DYPS-
MAMYSPSVC) possessing the same amino acid composi-
65 tion of the YSA peptide was tethered to the nanogels. The 
resultant nanogels should therefore possess the same physi-
cochemical surface properties as the YSA-labeled nanogels, 
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but should not specifically bind to the EphA2 receptor. FIG. 6 
shows the results of these studies, where cells incubated with 
YSA-labeled nanogels display -10-fold greater fluorescence 
relative to those incubated with SCR-labeled nanogels. Fur-
thermore, the fluorescence signal associated with cells incu-
bated with SCR-labelednanogels is only slightly greaterthan 
the cell autofluorescence background signal. 
The effect of nanogels on tumor cell toxicity and prolifera-
tion was examined using two cell viability assays. For the 
trypan blue exclusion assay, Hey cells were incubated with 
pNIPMAm nanogels, YSA-conjugated nanogels, or SCR-
conjugated nano gels for 72 hours. The cells were then washed 
with PBS, and trypan blue was added to the cells. Five fields 
were observed via microscopy for each treatment group. Blue 
cells, indicating dead cells, were not observed in any of the 
fields examined for any of the treatment groups (data not 
shown). To more precisely establish any negative effects asso-
ciated with nano gel-based delivery, we used the Tox 8 viabil-
ity proliferation assay. Hey cells were incubated in 96-well 
plates overnight and nano gels delivered and removed via the 
usual method. In the gene silencing data shown below, we 
chose siRNA targeting epidermal growth factor receptor 
(EGFR); knockdown of this receptor is non-lethal, but has 
clinical relevance in the treatment of drug resistant ovarian 
carcinomas. This siRNA was therefore used in these toxicity 
studies, as well. Again, we maintained a ratio of 1 mg nano-
gels/5xl 05 cells for all samples. For the EGFR siRNA-loaded 
nanogels, this corresponds to 16.6 µg siRNA/5xl05 cells. 
Wells were washed with PBS, and 100 µL of cell culture 
medium was added to the wells. After 72 hours, Tox 8 was 
added to the cells according to the manufacturer's instruc-
tions, and the cell viability was determined spectrophoto-
metrically. This analysis (FIG. 7) revealed no significant dif-
ference for any treatment when compared with control 
(untreated) cells, although exposure to non-targetednanogels 
and siRNA-containing nanogels showed slight decreases in 
viability; the origin of this effect is currently under investiga-
tion. These results indicate that treatment of Hey cells with 
targeted nanogels does not greatly inhibit cell proliferation, 
indicating limited toxicity of the nanogels under these con-
ditions. 
These promising studies clearly illustrate the efficacy of 
peptide-targeted delivery of siRNA cargos via nanogel carri-
ers. The lack of toxicity observed is of particular interest, 
given thehigh toxicity observed for some cationic lipid-based 
siRNA targeting methods, which limits the maximum doses 
that can be delivered, and also compromises the potential for 
in vivo delivery. In the present studies, a ratio of 16 µg siRNA 
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degradation in the endosomal or lysosomal compartments, or 
if the nanogels were unable to escape from endosomes in 
order to deliver the siRNA to the cytosol, the amount ofRNAi 
would be very low. Thus, we have undertaken a preliminary 
study of gene silencing to illustrate a minimal requirement for 
siRNA delivery: the functional silencing of a target mRNA. 
As described above, we chose siRNA targeting EGFR; 
knockdown of this receptor is non-lethal, but has clinical 
relevance in the treatment of drug resistant ovarian carcino-
10 mas. To determine if we could effectively knockdown EGFR 
in vitro, EGFR siRNA was encapsulated at a concentration of 
16.6 µg ofEGFR siRNA/mg ofnanogels, using the loading 
technique described above. Nanogels were then added to Hey 
cells (1 mg ofnanogels or 16.6 µg siRNA/5xl05 cells) and 
15 incubated at 37° C. for four hours. The unincorporated nano-
gels were then removed by washing the cells, and the medium 
was replaced. Controls included cells incubated with siRNA-
loaded but non-targeted pNIPMAm nanogels, unloaded 
YSA-targeted nanogels, pNIPMAm nanogels, and untreated 
20 cells. All cells were harvested at 48 hours and assayed for 
EGFR expression by immunoblotting. FIG. 8 shows the 
results of this experiment; a significant reduction in EGFR 
expression is observed under these conditions relative to all 
controls (p<0.01 relative to untreated sample by paired t-test, 
25 n=3). A small, statistically insignificant decrease in EGFR 
expression was noted in the unloaded, YSA-targeted nanogel 
control (p>0.1). If this observation is indeeda real one, it may 
be due to cross talk between the EGFR and the EphA2 recep-
tors, as described by Larsen and colleagues. In addition, a 
30 small decrease in EGFR expression was observed when cells 
were incubated with pNIPMAm nanogels alone, although the 
difference is not statistically significant (p>0.3) in light of the 
large observed variability in expression. 
These preliminary results illustrate that the targeted nano-
35 gels are capable of functional delivery of siRNA to ovarian 
carcinomas without overt toxic effects, and that the subse-
quently internalized siRNA is available for gene silencing. 
Conclusions. Peptide-labeled nano gels with a high loading 
capacity for siRNA have been developed and can be effec-
40 tively targeted to ovarian carcinomas by receptor-peptide 
binding. The encapsulated siRNA is transported into the cell 
interior, where it is available for gene silencing, as illustrated 
in this case by EGFR knockdown. Since the locus of siRNA-
mediated gene silencing is the cytosol, the results are sugges-
45 tive of the surprising conclusion that endosomal uptake of the 
nanogels is followed by endosomal escape, resulting in effi-
cient transport/release of the siRNA to the cytosol; however, 
we do not currently know the exact mechanism by which 
endosomal escape occurs. It is plausible that the nanogels or 1 mg nanogels/5xl05 cells was used throughout without 
significant toxicity being observed. These concentrations are 
somewhat higher than those suggested for common commer-
cial regents such as RNAiFect (Qiagen) or DharmaFECT 
(Dharmacon), suggesting that the nanogel approach is 
capable of delivering siRNA amounts at or above those 
achievable by optimized commercial reagents. Another com-
plicating factor in current methodologies is the frequent need 
for cellular delivery under serum free conditions; serum lipids 
and proteins compromise the stability of many liposomal 
formulations making their efficacy significantly lower. In the 
studies described herein, we have illustrated that delivery of 60 
siGLO is excellent in serum-containing medium, further 
establishing the promise of this construct. 
50 respond to endosomal changes in osmotic pressure and ionic 
strength by undergoing a volume change. This phenomenon, 
called osmotic swelling/deswelling is fundamental to the 
phase behavior of gel networks and may serendipitously be 
responsible for the excellent delivery properties described 
55 above. In addition to the gene-silencing efficacy, the nanocar-
riers are demonstrated to be non-toxic under the conditions 
investigated and are effective even when delivered in serum-
containing medium. 
Example 2 
Chemosensitization of Cancer Cells by SiRNA using 
Targeted Nanogel Delivery As a final preliminary test of the efficacy of the approach, 
we performed a limited investigation of siRNA-based silenc-
ing. Clearly, any delivery approach must deliver functional 65 
siRNA to the cell interior in order for it to be truly useful. If 
the nanogel carrier were unable to protect the cargo against 
Although a number of chemotherapeutic treatments have 
been shown to be effective at inhibiting or eliminating cancer 
cell growth in preclinical studies, clinical applications are 
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often limited due to the toxic side effects associated with 
anticancer drugs. Patients are often unable to tolerate the level 
of a drug needed to effectively eliminate malignant cells 
while levels that can be tolerated are insufficient therapeuti-
cally. As a result, chemoresistance and subsequent tumor 5 
recurrence are often the outcome of such therapies. An 
example of this all too common event is the use of taxanes 
(paclitaxel and its semi-synthetic analogue, docetaxel) in the 
treatment of a variety of cancers including ovarian, breast, 
prostate, and non-small cell lung cancers. While surgery 10 
along with taxane- and platinum-based chemotherapy for 
advanced ovarian cancer has allowed up to 80% of women to 
achieve a clinical response, cancers in most patients initially 
diagnosed with late stage disease eventually recur. 
Development of methods to circumvent resistance may 15 
ultimately improve the impact of adjuvant therapy, resulting 
in prolonged disease-free intervals and survival. Novel tar-
geted therapies that interfere with specific molecular signal-
ing pathways affecting cancer cell survival are being devel-
oped as potential treatment options to render cancer cells 20 
more sensitive to cytotoxic chemotherapy. Targeted therapies 
that increase cancer cell sensitivity to chemotherapies offer 
the benefits oflowering unwanted side effects and increasing 
the likelihood of destroying resistant cells while avoiding 
healthy cells where there is little or no expression of the 25 
targeted entity. 
Recent studies have shown that sensitivity of ovarian can-
cer cells to the taxane, paclitaxel, is enhanced when the drug 
is administered in combination with an inhibitor of EGFR. 
EGFR and its ligand, epidermal growth factor (EGF), play 30 
critical roles in the progression of ovarian cancer through 
their effects on cellular proliferation, apoptosis, angiogen-
esis, and metastasis. EGFR is overexpressed or dysregulated 
in many solid tumors, and high levels are expressed in 
33-98% of all epithelial ovarian cancers. Their high expres- 35 
sion is believed to mitigate the effectiveness of taxane che-
motherapy by inhibiting cell division and apoptosis. Reports 
of inhibition of EGFR with tyrosine kinase inhibitors (TKI) 
[e.g. gefitinib (Iressa)] and monoclonal antibodies (e.g. 
cetuximab) have demonstrated that silencing of receptor 40 
activity increases chemosensitization of tumor cells includ-
ing ovarian cancer cells. While targeting EGFR as well as 
other members of the human EGFR (HER) family has proven 
successful, not all tumors that are expected to respond to these 
agents do so. Often, emergence of drug resistance occurs 45 
either by targeted mutation or induction of alternative signal-
ing pathways. These results highlight the need for further 
targeted approaches. 
Based on these findings, we sought to determine if siRNA 
against EGFR could be selectively delivered to ovarian can- 50 
cer cells using a nanoparticle carrier. Targeted cancer therapy 
by RNA interference (RNAi) is a relatively new approach, 
and silencing EGFR by RNAi has already shown promising 
results. We report in the Example application of a novel and 
highly efficient method for the targeted delivery of EGFR 55 
siRNA to ovarian cancer cells. We used a 12 amino acid 
peptide (YSAYPDSVPMMS or "YSA") coupled to the sur-
face of -100-nm diameter core/shell nanogels [composed 
largely of poly(N-isopropylmethacrylamide) (pNIPMAnl)] 
to permit cell-specific targeting, and the subsequent delivery 60 
of high concentrations of EGFR siRNA. The YSA peptide 
mimics the ligand ephrin-Al, which binds to the erythropoi-
etin-producing hepatocellular (Eph) A2 receptor, while the 
core/shell nanogel offers an efficient vehicle for cell entry, a 
protective environment for the siRNA, and a depot for its 65 
controlled release. Delivery of nano gel-loaded EGFR siRNA 
to EphA2 positive cells resulted in the loss ofEGFR expres-
24 
sion followed by a significant increase in the sensitivity of the 
targeted cells to docetaxel. Our results indicate that this 
approach may lead to considerable improvements in the treat-
ment of ovarian and other cancers by increasing the efficacy 
of chemotherapy while simultaneously reducing the associ-
ated negative side effects. 
Materials and Methods. All materials were purchased from 
Sigma-Aldrich (St Louis, Mo.) and used as received unless 
otherwise noted. 
Nanogel synthesis. For the present Example, we utilized a 
nanogel structure that we have previously shown to have 
excellent siRNA encapsulation and release properties in the 
context of in vitro delivery. The synthesis of the nano gels has 
been described previously. Briefly, nanogel core particles 
were synthesized by free-radical precipitation polymeriza-
tion using a molar composition of 98% N-isopropyl-
methacrylamide (NIPMAnl), 2% N,N'-methylenebis(acryla-
mide) (BIS) and a small amount (-0.1 mM) 
acrylamidofluorescein (AFA) to render the nanogels fluores-
cent for visualization. The core nanogels were then used as 
seeds for the addition of a hydrogel shell [34, 35]. The shell 
composition was 97.5% NIPMAm, 2% BIS, and 0.5% ami-
nopropylmethacrylamide (APMA, Polysciences, War-
rington, Pa.). The APMA co-monomer was included to pro-
vide chemoligation sites for peptide immobilization. 
Peptide conjugation. The YSA peptide (GenScript Corpo-
ration, Piscataway, N.J.) was conjugated to the nanogels via 
maleimide coupling to the cysteine residue on the C-terminal 
end of the peptides. Maleimide-functionalized nano gels were 
prepared via EDC coupling of E-maleimidocaproic acid 
(EMCA) to the primary amines in the nanogel shell. Peptide 
coupling was performed by introducing the YSA peptide in a 
1: 1 molar ratio with amine (YSA molecular weight= 1450.66 
g/mol). The YSA peptide was then conjugated to the nano gels 
via maleimide coupling to the cysteine residue on the C-ter-
minal end of the peptides. 
Cell culture. Hey cells were provided by Gordon W Mills, 
Department of Systems Biology, the University of Texas, M. 
D. Anderson Cancer Center. Hey cells were cultured in RPMI 
1640 (Mediatech, Manassas, Va.) supplemented with 10% 
v/v heat-inactivated fetal calf serum (Invitrogen, Carlsbad, 
Calif.), 2 mM L-glutamine (Mediatech), 10 mM HEPES 
buffer (Mediatech), penicillin (100 U/ml), and streptomycin 
(100 µg/mL). SK-OV-3 cells were purchased from theAmeri-
can Type Culture Collection (ATCC, Manassas, Va.) and were 
propagated in McCoy's SA with L-glutamine (Mediatech) 
supplemented with 10% v/v heat-inactivated fetal calf serum 
(Atlanta Biologicals, Lawrenceville, Ga.), penicillin, and 
streptomycin (Mediatech). 
RNA encapsulation. Hydrogels were loaded with siRNA as 
previously described in Example 1. Briefly, lyophilized nano-
gels were reswollen in the presence of the siRNA, thereby 
imbibing the solute within the hydro gel network. In a typical 
procedure, a 20 µM solution (250 µL) ofEGFR siRNA (Dhar-
macon, Lafayette, Colo.) was prepared in phosphate buffered 
saline (PBS). Nanogels were resuspended in this mixture at a 
concentration of 4 mg per 250 µL of siRNA solution and 
allowed to shake overnight at room temperature. After the 
siRNA was encapsulated in the nanogels, they were centri-
fuged and resuspended to a final concentration of 10 mg/mL 
in cell culture medium or PBS. Based on this procedure, the 
final concentration of siRNA was determined to be 16.6 µg 
siRNA/mg ofnanogels. 
Immunoblotting. Hey or SK-OV-3 cells were plated into 
6-well cell culture plates (5xl05 cells/well), and the cells 
allowed to adhere overnight at 37° C. in a 5% C02 atmo-
sphere. After washing the wells with PBS and replacing the 
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media, EGFR siRNA-loaded/YSA-conjugated nanogels 
were added to the wells. Cells were incubated for 4 hours, 
washed with PBS, and fresh medium was added to the cells. 
The cells were incubated at 37° C. and 5% C02 in wells for 
24, 48, 72, 96, and 120 hours. Control wells were set up to 5 
include non-targeted/siRNA-encapsulated pNIPMAm par-
ticles, unloaded pNIPMAm particles, YSA alone, and 
untreated cells. Cells were lysed after the designated time 
points, and immunoblotting was carried out as described. To 
determine the optimal concentration ofEGFR-siRNA needed 10 
for efficient reduction ofEGFR expression, the nano gel load-
ing procedure described above was used, but the concentra-
tion of particles delivered to each well was altered. The initial 
concentration of siRNA-encapsulated particles (1 mg/mL of 
nanogels/5xl05 cells) used for the time point experiments 15 
was added to the first well. The concentration of subsequent 
wells was reduced by 10 fold each, resulting in nano gel 
concentrations oflOO, 10, and 1 ng/mL per 5xl05 cells.After 
4 hours of incubation with the nanogels, the cells were 
washed with PBS, and the medium was replaced. The cells 20 
were then incubated for an additional 48 hours, and the 
samples prepared for immunoblotting as described. 
Treatment with docetaxel. Hey or SK-OV-3 cells were 
plated in 96-well cell culture plates at a concentration of 
lxl04 cells/well. Hey or SK-OV-3 cells were subjected to 25 
nano gel delivery of siRNA at nano gel concentrations of 1000, 
100, 10, and 1 µg/mL. Forty-eight hours after siRNA delivery, 
docetaxel was added to Hey or SK-OV-3 cells at concentra-
tions ranging from 0.01-1000 nM. Treatment wells were set 
up in triplicate, and the cells were incubated with docetaxel 30 
for an additional 4 days. After treatment, the cells were 
washed with PBS, and 100 µL of medium was added back to 
the wells. To this, 10 µL ofTox8 was added to determine cell 
viability. The cells were incubated with the Tox8 reagent 
according to the manufacturer's instructions. The fluores- 35 
cence was measured O'-em =560 nm, "-ex =590 nm) by a Spec-
tramax Gemini Fluorescence Microplate Reader (Molecular 
Devices, Surmyvale, Calif.). Wells without cells but with 
Tox8 were used as controls and subtracted from all treatments 
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tion ofEGFR was noted in both cell lines by immunoblotting 
(FIG. 9B). Because of the observed differences in EphA2 
expression levels, we hypothesized that the level of EGFR 
siRNA delivery and the subsequent decrease in EGFR expres-
sion in the cell lines would depend upon the presence of the 
EphA2 receptor as well as the concentration of siRNA 
loaded-nanogels added to the cells. Based upon this premise, 
reduction of EGFR expression in SK-OV-3 cells (EphA2 
negative) should not be observed. 
To test this hypothesis and measure the efficacy of the 
siRNA loaded nanogels in our system, we determined the 
time course ofEGFR knockdown using EphA2 positive Hey 
cells. Lyophilized YSA-targeted nanogels were loaded with 
ofEGFR siRNA by reswelling the particles in a concentrated 
solution of siRNA, as described. This method results in high 
efficiency siRNA encapsulation (93±1 % ) and approximately 
70% retention of the siRNA after the first 12 hours. Long 
retention times may provide slow and continuous release of 
siRNA leading to pro longed reduction of the expressed target. 
Following siRNA encapsulation, the loaded nanogels were 
added to Hey cells and incubated at 37° C. for four hours. In 
all experiments, we maintained a constant nanogel/cell ratio 
of 1 mg/mL of nanogels/5xl 05 cells, unless noted. Unincor-
porated nanogels were removed by washing and subsequent 
replacement of the cell culture medium. Treated cells were 
incubated for an additional 24, 48, 72, 96, and 120 hours to 
determine the time course ofEGFR reduction by the nanogel-
delivered siRNA. At each time point, the cells were lysed and 
the samples were prepared for immunoblotting to determine 
the EGFR levels. FIG. lOA shows the average percent 
decrease in EGFR expression at each time point. A significant 
decrease in EGFR expression (*P<0.01) was observed at both 
48 and 72 hours when compared to untreated (UT) controls. 
Significance CP<0.05) was also observed at the 96 hour time 
point when compared to untreated cells. These results indi-
cate a maximum reduction of EGFR expression at 48 hours, 
and reexpression of EGFR beginning at approximately 72 
hours. Expression gradually increased through 120 hours but 
did not return to pretreatment levels. This may be due to the 
as background. Each experiment was performed in duplicate. 40 slow but continuous release of siRNA from the nanogels. A 
slight decrease in EGFR expression was noted in the 
unloaded, YSA-targeted nanogel control, which may be due 
to cross-talk between the EGFR and the EphA2 receptors. In 
addition, a small decrease in EGFR expression was observed 
Statistical analysis. Statistical analysis of the immunoblot 
data was performed using a non-parametric ANOVA 
(Kruskal Wallis) test. If significance was indicated, a Dunn's 
post-test was used to determine significance between groups. 
Statistical analysis of siRNA-loaded nano gels plus docetaxel 
treated Hey or SK-OV-3 cells was compared to all controls 
(pNIPMAm, YSA-pNIPMAm, YSA peptide alone, and 
untreated cells). To determine significance between groups, a 
one-way ANOVA test was performed. If significance was 
indicated, a Tukey post test was performed to determine sig- 50 
nificance between sample groups. In all cases, significance 
was defined as P<0.05. 
Results. Down-regulation ofEGFR in EphAr ovarian can-
cer (Hey) cells by targeted siRNA-loaded nanogels. By cou-
pling a peptide-mimetic (YSAYPDSVPMMS) of the EphA2 
receptor's ephrin-Al ligand to core/shell hydrogel nanopar-
ticles (nanogels), we demonstrated previously the ability to 
target the delivery of siRNA to ovarian cancer (Hey) cells 
expressing the EphA2 receptor. Importantly, these nanogels 
are nontoxic in both unmodified and targeted forms, and 
enabled the delivery of siRNA in serum-containing media. To 
further establish the efficacy and specificity of this targeting 
method, we established a model using ovarian cancer cell 
lines either positive or negative for expression of EphA2 and 
positive for expression of EGFR. FIG. 9A contrasts the high 
level ofEphA2 receptor expression by Hey cells with the lack 
ofEphA2 expression in the SK-OV-3 cancer cell line. Detec-
45 when cells were incubated with nanogels alone, but these 
decreases were not significant (P>0.05). A representative 
immunoblot is shown in FIG. lOB. 
To determine the dose response for the delivery vector, 
EGFR siRNA-loaded nanogels were incubated with Hey cells 
using 10-fold serial dilutions of siRNA-loaded nanogels so 
that the nanogel concentration ranged from 1 µg/mL to 1 
mg/mL per 5xl05 cells. Cells were harvested 48 hours after 
nanogel addition, and the cell lysates were analyzed by 
immunoblotting. Decreased levels ofEGFR were observed at 
55 all concentrations (FIG. llA). A significant decrease 
(*P<0.01) in EGFR expression was observed at the highest 
dose of delivered nanogels (1 mg/mL) when compared to 
YSA-targeted/unloaded nano gels, and complete reduction of 
EGFR expression was observed with as little as 10 µg/mL of 
60 siRNA-loaded nanogels. An immunoblot of a representative 
experiment is shown in FIG. llB. 
The role of the peptide-targeted receptor, EphA2, in nano-
gel uptake, and the level of nonspecific nanogel incorporation 
into cells were explored through the use of an EphA2 negative 
65 cell line, SK-OV-3. Because these cells lack EphA2 expres-
sion, we hypothesized that the YSA-targeted nano gels would 
not be taken up by SK-OV-3 cells through receptor-mediated 
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endocytosis of EphA2. Consequently, EGFR expression 
should not differ between targeted/siRNA-loaded nanogels 
and controls. Any particle uptake could then be designated as 
nonspecific. For these studies, siRNA (1 mg/mL ofnanogels) 
was loaded into YSA-pNIPMAm nanogels and added to 5 
5xl05 SK-OV-3 cells. Ten-fold serial dilutions of the nano-
viable strategy for treatment of cancers where frontline thera-
pies have failed to induce a cure. Chemosensitization by 
EGFR inhibition was demonstrated in early studies using 
blocking antibodies in combination with cisplatin or doxoru-
bicin in human tumor xenografts. This same effect was later 
observed using small TKis such as gefitinib (Iressa). Silenc-
gels were carried to assess the affects ofnanogel concentra-
tion on the levels ofEGFR. After 48 hours, harvested samples 
were examined for receptor expression by immunoblotting. 
As expected, expression of EGFR was not decreased after 
treatment with the loaded nanogels regardless of the concen-
tration ofnanogels used (FIG. 12). Expression levels in SK-
OV-3 cells treated with siRNA-loaded nano gels did not differ 
from controls demonstrating the high specificity of the tar-
geted nanogels for EphA2 positive cells but not for EphA2 
negative cells. 
Epidermal growth factor receptor down-regulation in 
siRNA-loaded nano gel treated cells sensitizes ovarian cancer 
cells to docetaxel. Expression of EGFR is significantly 
related to chemosensitivity in many cancers. The concept of 
chemosensitization by EGFR blockade was provided by stud-
ies utilizing EGFR-blocking antibodies in combination with 
cisplatin or doxorubicin in human tumor xenografts. Studies 
using a tyrosine kinase inhibitor against EGFR showed an 
increased sensitivity of ovarian cancer cell lines to paclitaxel 
after preincubation with the inhibitor. To determine if our 
targeted delivery of EGFR siRNA to ovarian cancer cells 
could be used to increase cell line sensitivity to taxanes, Hey 
cells were incubated with EGFR siRNA-loaded nanogel for 
48 hours to allow for maximum reduction in EGFR expres-
sion (see FIGS. lOA and B). After 48 hours, cells were treated 
with increasing concentrations of docetaxel (0.1 to 1000 nM), 
and the percent cytotoxicity was assessed. The results pre-
sented (FIG. 12A) demonstrate the docetaxel sensitivity of 
treated Hey cells was almost 8-fold greater than untreated 
controls. While Hey cells treated with nanogel controls also 
showed increased chemosensitivity (FIG. 12B), these 
changes were significantly less than those observed in cells 
treated with the YSA-targeted, siRNA-loaded nanogels 
(P<0.01). Exceptions included the pNIPMAM and YSA-
pNIPMAm controls where docetaxel concentrations were 
0-0.1 (P>0.05) at all nanogel concentrations examined, and 
for pNIPMAm and YSA-pNIPMAm controls when 1 ng/ml 
siRNA-loaded nanogels were delivered to cells followed by 
incubation with 1 nM docetaxel (P>0.05). Because SK-OV-3 
cells lack expression of EphA2, and thereby lack the means 
for receptor-mediated endocytosis of the targeted nano gels, 
we did not expect the sensitivity of SK-OV-3 cells to doc-
etaxel to be altered. Whereas an increase in cytotoxicity of the 
siRNA-loaded nanogel treated SK-OV-3 cells was noted as 
the concentration of docetaxel was increased, unlike the 
effect observed in the Hey cell line, sensitivity to the drug did 
not differ significantly from controls (P>0.05) (FIGS. 14A 
and B). These results corroborate our earlier findings that 
EGFR levels are not decreased in this cell line after treatment 
with siRNA-loaded nanogels. It also substantiates the high 
specificity of our peptide-targeted system, and demonstrates 
little or no nonspecific uptake ofnanogels by SK-OV-3 cells 
as shown by the constant levels of EGFR expression and 
unaltered chemosensitivity after nanogel treatment. 
Conclusion. Novel therapies that interfere with specific 
molecular signaling pathways have potential as treatment 
options since they render cancer cells more sensitive to cyto-
toxic therapy. Although the role of EGFR in altering tumor 
chemosensitivity has not yet been fully elucidated, preclinical 
studies have suggested that blockade ofEGFR, and the result-
ing reversal of chemoresistance in many tumor types is a 
ing ofEGFR by RNAi is an alternative to anti-EGFR therapy, 
and this approach has already shown promising results. 
While Example 1 demonstrated the specificity of YSA-
10 targeted siRNA-loaded nanogels to cells expressing EphA2, 
the studies presented in Example 2 serve as further validation 
of EphA2 as a target for translatable therapeutic strategies. 
The EphA2 receptor is overexpressed in a variety of cancers 
including - 7 5% of ovarian malignancies, and expression of 
15 the receptor is associated with poor prognosis, increased 
metastasis, and decreased survival. EphA2 shows limited 
expression in adults, with expression restricted to a few epi-
thelial tissues. Thus, due to its expression pattern, localiza-
tion, and functional importance in treatment outcome, EphA2 
20 is an attractive target for therapeutic agents in ovarian as well 
as other cancers. Several approaches have been used to target 
EphA2 for cancer therapy either by taking advantage of the 
tumor-promoting function ofEphA2 to modulate cell behav-
ior and suppress tumor growth, or using EphA2 as a means to 
25 deliver agents, such as exogenous drugs, to tumor cells and 
the tumor microenvironment. 
In this Example, we noticed that treatment of Hey cells 
with the YSA peptide showed diminished EGFR expression 
when compared to untreated controls (FIGS. lOA and B). 
30 Furthermore, Hey cells treated with the YSA peptide alone 
also showed an increased sensitivity to docetaxel when com-
pared to untreated controls (FIG. 13B). These differences 
were significant (P<0.05) at docetaxel doses of 1 nM and 
higher. Our results indicate that activation of EphA2 by the 
35 YSA peptide and subsequent EphA2 degradation may lead to 
a reduction in EGFR expression indicating cross-talk 
between the two receptor signaling pathways. In fact, two 
recent studies have shown that EphA2 interacts with mem-
bers of the EGFR receptor family, and these interactions may 
40 be important for targeted therapies involving EphA2 and 
EGFR. Mice harboring ErbB2 (a member of the EGFR fam-
ily) in mammary epithelium were sensitive to inhibition of 
EphA2 when compared to controls without ErbB2. EphA2 
formed a complex with ErbB2 in both human and murine 
45 breast carcinoma cells, leading to enhanced signaling through 
Ras-MAPK activation and ultimately promoting tumor pro-
gression. In addition, activated EGFR and the constitutively 
active EGFR type III deletion mutant (EGFRvIII) were 
shown to induce the expression ofEphA2 in manimalian cell 
50 lines. Loss of EphA2 expression reduced cell motility of 
EGFR-overexpressing cell lines. Thus, the interaction of 
EphA2 with members of the EGFR family indicates a func-
tional role for EphA2 in EGFR-expressing cancer cells. In our 
system, loss or reduction ofEphA2 through interaction with 
55 YSA-functionalized nanogels may provide an enhanced 
effect over delivery ofEGFR siRNA alone leading to a dual-
targeting strategy for chemosensitzation of ovarian tumors. 
The ability of siRNAs to potently but reversibly silence 
genes in vivo has made them particularly well suited as a drug 
60 therapeutic. However, poor stability under physiological con-
ditions limits the utility of systemic delivery of siRNA, and its 
high molecular weight (-13 kDa) and polyanionic nature 
prevent transport across the cell membrane, further com-
pounding the problem of therapeutic application. Thus, deliv-
65 ery represents the main hurdle for broader development of 
siRNA therapeutics. To our knowledge, the work presented 
here along with our previous studies, provides the first 
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description using targeted, poly(alkylacrylamide)-based 
nanogels for siRNA delivery. Furthermore, the core/shell 
nano gel delivery system employed here is readily amendable 
to selective surface functionalization by a variety of targeting 
molecules, offers a protective environment for sensitive 
cargo, and shows excellent targeting uptake and delivery in 
serum containing medium. The nanogel particles are also 
exceedingly simple to load, and extremely high (>90%) 
degrees of siRNA incorporation are observed. These proper-
ties and the low toxicity levels indicated thus far by this 
formulation along with the low immunotoxcity demonstrated 
recently by Li et al [28] indicate the promise of overcoming 
some of the final obstacles hindering siRNA driven therapeu-
tic strategies. Future studies investigating the in vivo delivery 
30 
3. The nanogel-based delivery system of claim 2, wherein 
the active agent is a small interfering ribonucleic acid 
(siRNA). 
4. The nanogel-based delivery system of claim 3, wherein 
the siRNA comprises substantial sequence identity to a target 
gene expressed in a neoplastic disease. 
5. The nanogel-based delivery system of claim 1, wherein 
the nanogel further comprises a targeting moiety, wherein the 
targeting moiety is attached to the crosslinked polymer shell 
10 
through the functionalization agent, and wherein the targeting 
moiety is displayed on at least a portion of the crosslinked 
polymer shell. 
of siRNAs to tumors using nanogels, and the effect on 15 
chemosensitization will aid in the refinement of targeted 
siRNA delivery for treatment of ovarian cancer. 
6. The nanogel-based delivery system of claim 5, wherein 
the targeting moiety comprises a peptide having the amino 
acid sequence YSAYPDSVPMMSC (SEQ ID NO: 1 ). 
7. The nanogel-based delivery system of claim 6, wherein 
the active agent comprises a siRNA having substantial 
sequence identity to a gene encoding epidermal growth factor 
receptor. 
SEQUENCES 
SEQ ID NO 1 
8. A method of delivering an active agent into a cell, the 
20 method comprising: 
Tyr-Ser-Ala-Tyr-Pro-Asp-Ser-Val-Pro-Met-Met-Ser-Cys 
SEQ ID NO 2 
Asp-Tyr-Pro-Ser-Met-Ala-Met-Tyr-Ser-Pro-Ser-Val-Cys 
<160> NUMBER OF SEQ ID NOS, 2 
<210> SEQ ID NO 1 
<211> LENGTH, 13 
<212> TYPE, PRT 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 1 
SEQUENCE LISTING 
Tyr Ser Ala Tyr Pro Asp Ser Val Pro Met Met Ser Cys 
1 5 10 
<210> SEQ ID NO 2 
<211> LENGTH, 13 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, SCRAMBLED FORM OF SEQ ID NO 1 
<400> SEQUENCE, 2 
Asp Tyr Pro Ser Met Ala Met Tyr Ser Pro Ser Val Cys 
1 5 10 
What is claimed is: 
contacting a nanogel with a cell, the nanogel comprising 
a crosslinked polymer particle wherein the crosslinked 
polymer particle comprises poly(N-isopropyl-
methacrylamide) and N,N'-methylenebis(acryla-
mide), 
a crosslinked polymer shell disposed substantially 
around the crosslinked polymer particle and compris-
ing a functionalization agent, and 
the active agent contained substantially within the nano-
gel, wherein the active agent is non-covalently asso-
ciated with the nanogel; and 
delivering the active agent to the cell. 
9. The method of claim 8, wherein the active agent com-
prises a siRNA. 
1. A nanogel-based delivery system comprising: a nanogel 
comprising a crosslinked polymer particle and a crosslinked 55 
polymer shell, disposed substantially around the crosslinked 
polymer particle; and an active agent contained substantially 
within the nano gel, wherein the active agent is non-covalently 
associated with thenanogel; wherein the crosslinked polymer 
particle comprises poly(N-isopropylmethacrylamide) and 60 
N,N'-methylenebis(acrylamide), and the crosslinked poly- 10. The method of claim 9, wherein the nanogel further 
comprises a targeting moiety and the crosslinked polymer 
shell comprises poly(N-isopropylmethacrylamide), N,N'-
65 methylenebis(acrylamide ), and aminopropylmethacryamide, 
wherein the targeting moiety is attached to the crosslinked 
polymer shell through the functionalization agent, and 
mer shell comprises a functionalization agent. 
2. The nanogel-based delivery system of claim 1, wherein 
the crosslinked polymer shell comprises poly(N-isopropyl-
methacrylamide), N,N'-methylenebis(acrylamide), and ami-
nopropylmethacryamide. 
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wherein the targeting moiety is displayed on at least a portion 
of the crosslinked polymer shell. 
11. The method of claim 10, further comprising reducing 
expression of a target gene, wherein the siRNA has substan-
tial sequence identity to the target gene. 
12. The method of claim 11, wherein the target gene 
encodes one or more of an anti- apoptotic molecule, a growth 
factor, a growth factor receptor, a mitotic spindle protein, a 
cell cycle protein, an angiogenic factor, an oncogene, an 
intracellular signal transducer, or a molecular chaperone. 
13. The method of claim 12, wherein the targeting moiety 
comprises a peptide having the amino acid sequence YSAY-
PDSVPMMSC (SEQ ID NO: 1 ), and wherein the active agent 
is a siRNA having substantial sequence identity to the target 
gene, the target gene encoding epidermal growth factor recep-
tor. 
14. A method for treating neoplastic disease comprising: 
administering to a subject having neoplastic disease an 
effective amount of a nano gel comprising 
a crosslinked polymer particle; 
a crosslinked polymer shell comprising a functionalization 
agent, wherein the crosslinked polymer shell is disposed 
substantially around the crosslinked polymer particle; 
32 
an active agent contained substantially within the nano gel, 
wherein the active agent is non-covalently associated 
with the nanogel; 
wherein the neoplastic disease comprises cells expressing 
the EphA2 receptor. 
15. The method of treating neoplastic disease of claim 14, 
wherein the crosslinked polymer particle comprises poly(N-
isopropylmethacrylamide) and N,N'-methylenebis (acryla-
mide ), and wherein the crosslinked polymer shell comprises 
10 poly(N-isopropylmethacrylamide), N,N'-methylenebis (acrylamide), and aminopropylmethacryamide. 
16. The method of treating neoplastic disease of claim 15, 
further comprising reducing expression of a target gene, 
wherein the active agent is a siRNA, the siRNA having sub-
15 stantial sequence identity to the target gene, and wherein the 
target gene encodes one or more of an anti-apoptotic mol-
ecule, a growth factor, a growth factor receptor, a mitotic 
spindle protein, a cell cycle protein, an angiogenic factor, an 
oncogene, an intracellular signal transducer, or a molecular 
20 chaperone. 
17. The method of treating neoplastic disease of claim 16, 
wherein the target gene encodes epidermal growth factor 
receptor. 
a targeting moiety comprising a peptide having the amino 25 
acid sequence YSAYPDSVPMMSC (SEQ ID NO: 1 ), 
wherein the targeting moiety is attached to the 
crosslinked polymer shell through the functionalization 
agent, and wherein the targeting moiety is displayed on 
18. The method of treating neoplastic disease of claim 17, 
further comprising increasing sensitivity of the subject to a 
chemotherapeutic agent. 
19. The method of treating neoplastic disease of claim 18, 
wherein the chemotherapeutic agent comprises paclitaxel or 
docetaxel. 
at least a portion of the crosslinked polymer shell; and 
* * * * * 
